var title_f4_58_5024="Selected agents with potential adverse fetal effects";
var content_f4_58_5024=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected agents with potential adverse fetal effects",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Reproductive toxin",
"           </td>",
"           <td class=\"subtitle1\">",
"            Alleged effects",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aminopterin, methotrexate",
"           </td>",
"           <td>",
"            Growth retardation, microcephaly, meningomyelocele, mental retardation, hydrocephalus, and cleft palate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Androgens",
"           </td>",
"           <td>",
"            Masculinization of the developing female fetus can occur from androgens and high doses of some male-derived progestins.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers",
"           </td>",
"           <td>",
"            Fetal hypotension syndrome in second and third trimester resulting in fetal kidney hypoperfusion and anuria, oligohydramnios, pulmonary hypoplasia, and cranial bone hypoplasia. Heart defects from 1st trimester exposure.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antidepressants",
"           </td>",
"           <td>",
"            Recent publications have implicated some of the SSRIs administered in the last trimester with postnatal neurobehavioral effects that are transient and whose long-term effects have not been determined. First-trimester exposures to some SSRIs have been reported to increase the risk of some congenital malformations, predominantly congenital heart disease. The results have not been consistent, but warnings have been issued.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antituberculous therapy",
"           </td>",
"           <td>",
"            Isoniazid and paraaminosalicylic acid have an increased risk for some CNS abnormalities.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Caffeine",
"           </td>",
"           <td>",
"            Moderate caffeine exposure is not associated with birth defects; high exposures are associated with an increased risk of abortion but the data are inconsistent.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chorionic villous sampling (&lt;10 weeks)",
"           </td>",
"           <td>",
"            Vascular disruption malformations (ie, limb-reduction defects)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cobalt in hematemic multivitamins",
"           </td>",
"           <td>",
"            Fetal goiter",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cocaine",
"           </td>",
"           <td>",
"            Vascular disruptive type malformations in very low incidence; pregnancy loss.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Corticosteroids",
"           </td>",
"           <td>",
"            High exposures administered systemically have a low risk for cleft palate in some studies, but the epidemiologic studies are not consistent.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cyclophosphamide and other chemotherapeutic agents and immunosuppressive agents (eg, cyclosporine, leflunomide)",
"           </td>",
"           <td>",
"            Many chemotherapeutic agents used to treat cancer have a theoretical risk for producing malformations in the fetus when administered to pregnant women, especially because most of these drugs are teratogenic in animals, but the clinical data are not consistent. Many of these drugs have not been shown to be teratogenic, but the numbers of cases in the studies are small. Caution is the byword.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diethylstilbestrol",
"           </td>",
"           <td>",
"            Administration during pregnancy produces genital abnormalities, adenosis, and clear cell adenocarcinoma of vagina in adolescents. The last has a risk of 1:1000 to 1:10,000, but the other effects, such as adenosis, can be quite high.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ethyl alcohol",
"           </td>",
"           <td>",
"            Fetal alcohol syndrome consists of microcephaly, mental retardation, growth retardation, typical facial dysmorphogenesis, abnormal ears, small palpebral fissures.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ionizing radiation",
"           </td>",
"           <td>",
"            Radiation exposure above a threshold of 20 rad (0.2 Gy) can increase the risk for some fetal effects such as microcephaly or growth retardation, but the threshold for mental retardation is higher.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Insulin shock therapy",
"           </td>",
"           <td>",
"            Insulin shock therapy, when administered to pregnant women, resulted in microcephaly, mental retardation.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lithium therapy",
"           </td>",
"           <td>",
"            Chronic usage for the treatment of manic depressive illness has an increased risk for Ebstein's anomaly and other malformations, but the risk seems to be very low.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Minoxidil",
"           </td>",
"           <td>",
"            This drug's promotion of hair growth was discovered because administration during pregnancy resulted in hirsutism in newborns.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methimazole",
"           </td>",
"           <td>",
"            Aplasia cutis has been reported to be increased in mothers administered this drug during pregnancy*.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methylene blue intra-amniotic instillation",
"           </td>",
"           <td>",
"            Fetal intestinal atresia, hemolytic anemia, and jaundice in neonatal period. This procedure is no longer used to identify one twin.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Misoprostol",
"           </td>",
"           <td>",
"            A low incidence of vascular disruptive phenomenon, such as limb-reduction defects and Mobius syndrome, has been reported in pregnancies in which this drug was used to induce an abortion.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mycophenolate mofetil",
"           </td>",
"           <td>",
"            1st trimester exposure associated with miscarriage, abnormalities of the ear, distal limbs, heart, esophagus, kidney, and cleft lip/palate.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Penicillamine (D-penicillamine)",
"           </td>",
"           <td>",
"            This drug results in the physical effects referred to as \"lathyrism,\" the results of poisoning by the seeds of the genus",
"            <em>",
"             Lathyrus",
"            </em>",
"            . It causes collagen disruption, cutis laxa, and hyperflexibility of joints. The condition seems to be reversible, and the risk is low.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Progestin therapy",
"           </td>",
"           <td>",
"            Very high doses of androgen hormone-derived progestins can produce masculinization. Many drugs with progestational activity do not have masculinizing potential. None of these drugs have the potential for producing nongenital malformations.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Propylthiouracil",
"           </td>",
"           <td>",
"            This drug and other antithyroid medications administered during pregnancy can result in an infant born with a goiter.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Radioactive isotopes",
"           </td>",
"           <td>",
"            Tissue- and organ-specific damage depends on the radioisotope element and distribution (ie, high doses of Iodine-131 administered to a pregnant woman can cause fetal thyroid hypoplasia after the eighth week of development).",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Retinoids",
"           </td>",
"           <td>",
"            Systemic retinoic acid, isotretinoin, and etretinate can cause increased risk of CNS, cardioaortic, ear, and clefting defects such as microtia, anotia, thymic aplasia, other branchial arch and aortic arch abnormalities, and certain congenital heart malformations.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Retinoids, topical",
"           </td>",
"           <td>",
"            Topical administration is very unlikely to have teratogenic potential, because teratogenic serum levels cannot be attained by topical exposure to retinoids.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Streptomycin",
"           </td>",
"           <td>",
"            Streptomycin and a group of ototoxic drugs can affect the eighth nerve and interfere with hearing; it is a relatively low-risk phenomenon. Children are less sensitive than adults to the ototoxic effects of these drugs.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfa drugs and vitamin K",
"           </td>",
"           <td>",
"            These drugs can produce hemolysis in some subpopulations of fetuses.",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Reproductive toxin",
"           </td>",
"           <td class=\"subtitle1\">",
"            Alleged effects",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tetracycline",
"           </td>",
"           <td>",
"            This drug produces bone and teeth staining, it does not increase the risk of any other malformations.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thalidomide",
"           </td>",
"           <td>",
"            This drug results in an increased incidence of deafness, anotia, preaxial limb-reduction defects, phocomelia, ventricular septal defects, and gastrointestinal atresias. The susceptible period is from the twenty-second to the thirty-sixth day after conception.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trimethoprim",
"           </td>",
"           <td>",
"            This drug was used frequently to treat urinary tract infections and has been linked to an increased incidence of neural tube defects. The risk is not high, but it is biologically plausible because of the drug's effect on lowering folic acid levels, which has resulted in neurologic symptoms in adults taking this drug.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vitamin A",
"           </td>",
"           <td>",
"            The malformations reported with the retinoids have been reported with very high doses of vitamin A (retinol). Dosages to produce birth defects would have to be in excess of 25,000 to 50,000 units/d.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Warfarin and warfarin derivatives",
"           </td>",
"           <td>",
"            Early exposure during pregnancy can result in nasal hypoplasia, stippling of secondary epiphysis, intrauterine growth restriction. Central nervous system malformations can occur in late pregnancy exposure because of bleeding.",
"           </td>",
"          </tr>",
"          <tr class=\"divider_top\">",
"           <td class=\"subtitle2_left\" colspan=\"2\">",
"            Anticonvulsants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Phenytoin",
"           </td>",
"           <td>",
"            Increases risk of fetal hydantoin syndrome, consisting of facial dysmorphology, cleft palate, ventricular septal defect, and growth and mental retardation.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Trimethadione and paramethadione",
"           </td>",
"           <td>",
"            Increases the risk of characteristic facial dysmorphology, mental retardation, V-shaped eyebrows, low-set ears with anteriorly folded helix, high-arched palate, irregular teeth, CNS anomalies, and severe developmental delay.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Valproic acid",
"           </td>",
"           <td>",
"            Increases the risk of spina bifida, facial dysmorphology, autism, atrial septal defect, cleft palate, hypospadias, polydactyly, and craniosynostosis.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Carbamazepine",
"           </td>",
"           <td>",
"            Increases the risk facial dysmorphology, neural tube defects, cardiovascular defects, and urinary tract defects.",
"           </td>",
"          </tr>",
"          <tr class=\"divider_top\">",
"           <td class=\"subtitle2_left\" colspan=\"2\">",
"            Chemicals",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Carbon monoxide poisoning",
"           </td>",
"           <td>",
"            Central nervous system damage has been reported with very high exposures, but the risk seems to be low*.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lead",
"           </td>",
"           <td>",
"            Very high exposures can cause pregnancy loss; intrauterine teratogenesis is not established at very low exposures below 20 microgram/percent in the serum of pregnant mothers.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gasoline addiction embryopathy",
"           </td>",
"           <td>",
"            Facial dysmorphology, mental retardation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Methyl mercury",
"           </td>",
"           <td>",
"            Minamata disease consists of cerebral palsy, microcephaly, mental retardation, blindness, and cerebellum hypoplasia. Other epidemics have occurred from adulteration of wheat with mercurycontaining chemicals that are used to prevent grain spoilage. Present environmental levels of mercury are unlikely to represent a teratogenic risk, but reducing or limiting the consumption of carnivorous fish has been suggested to avoid exceeding the maximum permissible exposure recommended by the Environmental Protection Agency, an exposure level far below the level at which the toxic effects of mercury are seen.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Polychlorinated biphenyls",
"           </td>",
"           <td>",
"            Poisoning has occurred from adulteration of food products (\"Cola-colored babies,\" CNS effects, pigmentation of gums, nails, teeth, and groin; hypoplastic deformed nails; intrauterine growth retardation; abnormal skull calcification). The threshold exposure has not been determined, but it is unlikely to be teratogenic at the present environmental exposures.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Toluene addiction embryopathy",
"           </td>",
"           <td>",
"            Facial dysmorphology, mental retardation",
"           </td>",
"          </tr>",
"          <tr class=\"divider_top\">",
"           <td class=\"subtitle2_left\" colspan=\"2\">",
"            Embryonic and fetal infections",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cytomegalovirus infection",
"           </td>",
"           <td>",
"            Retinopathy, CNS calcification, microcephaly, mental retardation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rubella",
"           </td>",
"           <td>",
"            Deafness, congenital heart disease, microcephaly, cataracts, mental retardation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Herpes simplex",
"           </td>",
"           <td>",
"            Fetal infection, liver disease, death",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            HIV",
"           </td>",
"           <td>",
"            Perinatal HIV infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Parvovirus infection, B19",
"           </td>",
"           <td>",
"            Stillbirth, hydrops",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Syphilis",
"           </td>",
"           <td>",
"            Maculopapular rash, hepatosplenomegaly, deformed nails, osteochondritis at joints of extremities, congenital neurosyphilis, abnormal epiphyses, chorioretinitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Toxoplasmosis",
"           </td>",
"           <td>",
"            Hydrocephaly, microphthalmia, chorioretinitis, mental retardation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Varicella zoster",
"           </td>",
"           <td>",
"            Skin and muscle defects; intrauterine growth retardation; limb reduction defects, CNS damage (very low increased risk)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Venezuelan equine encephalitis",
"           </td>",
"           <td>",
"            Hydranencephaly; microphthalmia; destructive CNS lesions; luxation of hip",
"           </td>",
"          </tr>",
"          <tr class=\"divider_top\">",
"           <td class=\"subtitle2_left\" colspan=\"2\">",
"            Maternal disease states",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Corticosteroid-secreting endocrinopathy",
"           </td>",
"           <td>",
"            Mothers who have Cushing's disease can have infants with hyperadrenocortism, but anatomic malformations do not seem to be increased.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Iodine deficiency",
"           </td>",
"           <td>",
"            Can result in embryonic goiter and mental retardation.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Intrauterine problems of constraint and vascular disruption",
"           </td>",
"           <td>",
"            These defects are more common in multiple-birth pregnancies, pregnancies with anatomic defects of the uterus, placental emboli, or amniotic bands. Possible birth defects include club feet, limb-reduction defects, aplasia cutis, cranial asymmetry, external ear malformations, midline closure defects, cleft palate and muscle aplasia, cleft lip, omphalocele, and encephalocele).",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Maternal androgen endocrinopathy (adrenal tumors)",
"           </td>",
"           <td>",
"            Masculinization of female fetuses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Maternal diabetes with poor glycemic control",
"           </td>",
"           <td>",
"            Increases the risk of a wide variety of congenital anomalies; cardiac abnormalites are most common.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Maternal folic acid in reduced amounts",
"           </td>",
"           <td>",
"            An increased incidence of neural tube defects.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Maternal phenylketonuria",
"           </td>",
"           <td>",
"            Abortion, microcephaly, and mental retardation; very high risk in untreated patients.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Maternal starvation",
"           </td>",
"           <td>",
"            Intrauterine growth restriction, abortion, neural tube defects (Dutch famine experience)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tobacco smoking",
"           </td>",
"           <td>",
"            Abortion, intrauterine growth restriction, stillbirth",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Zinc deficiency*",
"           </td>",
"           <td>",
"            Neural tube defects*",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CNS: central nervous system.",
"     <br>",
"      * Controversial.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Brent, RL. How does a physician avoid prescribing drugs and medical procedures that have reproductive and developmental risks? Clin Perinatol 2007; 34:233. Copyright &copy; 2007 Elsevier.",
"     <br>",
"      Updated July 15, 2010 Gerald Briggs, B.Pharm.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_58_5024=[""].join("\n");
var outline_f4_58_5024=null;
var title_f4_58_5025="Genes associated with nonsyndromic dilated cardiomyopathy";
var content_f4_58_5025=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genes associated with nonsyndromic dilated cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Gene*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Protein",
"       </td>",
"       <td class=\"subtitle1\">",
"        Function",
"       </td>",
"       <td class=\"subtitle1\">",
"        OMIM",
"       </td>",
"       <td class=\"subtitle1\">",
"        Estimated fraction*",
"        <span class=\"small\">",
"         &bull;",
"        </span>",
"       </td>",
"       <td class=\"subtitle1\">",
"        References",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Autosomal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"6\">",
"        DCM phenotype",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &nbsp;TTN",
"       </td>",
"       <td>",
"        Titin&nbsp;",
"       </td>",
"       <td>",
"        Sarcomere structure/extensible scaffold for other proteins",
"       </td>",
"       <td>",
"        188840&nbsp;",
"       </td>",
"       <td>",
"        &nbsp;0.20",
"       </td>",
"       <td>",
"        42, 43, 67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        MYH7",
"       </td>",
"       <td>",
"        &beta;-myosin heavy chain",
"       </td>",
"       <td>",
"        Sarcomeric protein; muscle contraction",
"       </td>",
"       <td>",
"        160760",
"       </td>",
"       <td>",
"        0.042",
"       </td>",
"       <td>",
"        1-4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        MYH6",
"       </td>",
"       <td>",
"        &alpha;-myosin heavy chain",
"       </td>",
"       <td>",
"        Sarcomeric protein; muscle contraction",
"       </td>",
"       <td>",
"        160710",
"       </td>",
"       <td>",
"        0.043",
"       </td>",
"       <td>",
"        5, 6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        MYPN",
"       </td>",
"       <td>",
"        Myopalladin",
"       </td>",
"       <td>",
"        Sarcomeric protein, z-disc",
"       </td>",
"       <td>",
"        608517",
"       </td>",
"       <td>",
"        0.035",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        TNNT2",
"       </td>",
"       <td>",
"        Cardiac troponin T",
"       </td>",
"       <td>",
"        Sarcomeric protein; muscle contraction",
"       </td>",
"       <td>",
"        191045",
"       </td>",
"       <td>",
"        0.029",
"       </td>",
"       <td>",
"        1, 3, 4, 8-11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        MYBPC3",
"       </td>",
"       <td>",
"        Myosin-binding protein C",
"       </td>",
"       <td>",
"        Sarcomeric protein; muscle contraction",
"       </td>",
"       <td>",
"        600958",
"       </td>",
"       <td>",
"        0.02",
"       </td>",
"       <td>",
"        2, 6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        RBM20",
"       </td>",
"       <td>",
"        RNA binding protein 20",
"       </td>",
"       <td>",
"        RNA binding protein of the spliceosome",
"       </td>",
"       <td>",
"        613171",
"       </td>",
"       <td>",
"        0.019",
"       </td>",
"       <td>",
"        12, 13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        TMPO",
"       </td>",
"       <td>",
"        Thymopoietin",
"       </td>",
"       <td>",
"        Also LAP2; a lamin-associated nuclear protein",
"       </td>",
"       <td>",
"        188380",
"       </td>",
"       <td>",
"        0.011",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        LAMA4",
"       </td>",
"       <td>",
"        Laminin a-4",
"       </td>",
"       <td>",
"        Extracellular matrix protein",
"       </td>",
"       <td>",
"        600133",
"       </td>",
"       <td>",
"        0.011",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        VCL",
"       </td>",
"       <td>",
"        Metavinculin",
"       </td>",
"       <td>",
"        Sarcomere structure; intercalated discs",
"       </td>",
"       <td>",
"        193065",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        3, 16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        LDB3",
"       </td>",
"       <td>",
"        Cypher",
"       </td>",
"       <td>",
"        Cytoskeletal assembly; targeting/clustering of membrane proteins",
"       </td>",
"       <td>",
"        605906",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        4, 17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        TCAP",
"       </td>",
"       <td>",
"        Titin-cap or telethonin",
"       </td>",
"       <td>",
"        Z-disc protein that associates with titin; aids sarcomere assembly",
"       </td>",
"       <td>",
"        604488",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        4, 18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        PSEN1/2",
"       </td>",
"       <td>",
"        Presenilin 1 / 2",
"       </td>",
"       <td>",
"        Transmembrane proteins, gamma secretase activity",
"       </td>",
"       <td>",
"        104311/ 600759",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        ACTN2",
"       </td>",
"       <td>",
"        &alpha;-actinin-2",
"       </td>",
"       <td>",
"        Sarcomere structure; anchor for myofibrillar actin",
"       </td>",
"       <td>",
"        102573",
"       </td>",
"       <td>",
"        0.009",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        CRYAB",
"       </td>",
"       <td>",
"        Alpha B crystallin",
"       </td>",
"       <td>",
"        Cytoskeletal protein",
"       </td>",
"       <td>",
"        123590",
"       </td>",
"       <td>",
"        0.007",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        TPM1",
"       </td>",
"       <td>",
"        &alpha;-tropomyosin",
"       </td>",
"       <td>",
"        Sarcomeric protein; muscle contraction",
"       </td>",
"       <td>",
"        191010",
"       </td>",
"       <td>",
"        0.006",
"       </td>",
"       <td>",
"        6, 22, 23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        ABCC9",
"       </td>",
"       <td>",
"        SUR2A",
"       </td>",
"       <td>",
"        Kir6.2 regulatory subunit, inwardly rectifying cardiac KATP channel",
"       </td>",
"       <td>",
"        601439",
"       </td>",
"       <td>",
"        0.006",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        ACTC",
"       </td>",
"       <td>",
"        Cardiac actin",
"       </td>",
"       <td>",
"        Sarcomeric protein; muscle contraction",
"       </td>",
"       <td>",
"        102540",
"       </td>",
"       <td>",
"        0.005",
"       </td>",
"       <td>",
"        25-30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        PDLIM3",
"       </td>",
"       <td>",
"        PDZ LIM domain protein 3",
"       </td>",
"       <td>",
"        Cytoskeletal protein",
"       </td>",
"       <td>",
"        605889",
"       </td>",
"       <td>",
"        0.005",
"       </td>",
"       <td>",
"        31",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        ILK",
"       </td>",
"       <td>",
"        Integrin-linked kinase",
"       </td>",
"       <td>",
"        Intracellular serine-threonine kinase; interacts with integrins",
"       </td>",
"       <td>",
"        602366",
"       </td>",
"       <td>",
"        0.005",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        TNNC1",
"       </td>",
"       <td>",
"        Cardiac troponin C",
"       </td>",
"       <td>",
"        Sarcomeric protein; muscle contraction",
"       </td>",
"       <td>",
"        191040",
"       </td>",
"       <td>",
"        0.004",
"       </td>",
"       <td>",
"        6, 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        TNNI3",
"       </td>",
"       <td>",
"        Cardiac troponin I",
"       </td>",
"       <td>",
"        Sarcomeric protein, muscle contraction; also seen as recessive",
"       </td>",
"       <td>",
"        191044",
"       </td>",
"       <td>",
"        0.004",
"       </td>",
"       <td>",
"        6, 32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        PLN",
"       </td>",
"       <td>",
"        Phospholamban",
"       </td>",
"       <td>",
"        Sarcoplasmic reticulum Ca++ regulator; inhibits SERCA2 pump",
"       </td>",
"       <td>",
"        172405",
"       </td>",
"       <td>",
"        0.004",
"       </td>",
"       <td>",
"        3, 33-36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        DES",
"       </td>",
"       <td>",
"        Desmin",
"       </td>",
"       <td>",
"        DAGC; transduces contractile forces",
"       </td>",
"       <td>",
"        125660",
"       </td>",
"       <td>",
"        0.003",
"       </td>",
"       <td>",
"        28, 37, 38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        SGCD",
"       </td>",
"       <td>",
"        &delta;-sarcoglycan",
"       </td>",
"       <td>",
"        DAGC; transduces contractile forces",
"       </td>",
"       <td>",
"        601411",
"       </td>",
"       <td>",
"        0.003",
"       </td>",
"       <td>",
"        38-40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        CSRP3",
"       </td>",
"       <td>",
"        Muscle LIM protein",
"       </td>",
"       <td>",
"        Sarcomere stretch sensor/ Z discs",
"       </td>",
"       <td>",
"        600824",
"       </td>",
"       <td>",
"        0.003",
"       </td>",
"       <td>",
"        4, 41",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        EYA4",
"       </td>",
"       <td>",
"        Eyes-absent 4",
"       </td>",
"       <td>",
"        Transcriptional coactivators (Six and Dach)",
"       </td>",
"       <td>",
"        603550",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        44",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        ANKRD1",
"       </td>",
"       <td>",
"        Ankyrin repeat domain-containing protein 1",
"       </td>",
"       <td>",
"        Cardiac ankyrin repeat protein (CARP); localized to myopalladin/titin complex",
"       </td>",
"       <td>",
"        609599",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        NEBL",
"       </td>",
"       <td>",
"        Nebulette",
"       </td>",
"       <td>",
"        Binds actin; Z-disc protein",
"       </td>",
"       <td>",
"        605491",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        46",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"6\">",
"        DCM with prominent conduction system disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        LMNA",
"       </td>",
"       <td>",
"        Lamin A/C",
"       </td>",
"       <td>",
"        Structure/stability of inner nuclear membrane; gene expression",
"       </td>",
"       <td>",
"        150330",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"       <td>",
"        47-60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        SCN5A",
"       </td>",
"       <td>",
"        Sodium channel",
"       </td>",
"       <td>",
"        Controls sodium ion flux",
"       </td>",
"       <td>",
"        600163",
"       </td>",
"       <td>",
"        0.026",
"       </td>",
"       <td>",
"        4, 61, 62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        X-linked",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        DMD",
"       </td>",
"       <td>",
"        Dystrophin",
"       </td>",
"       <td>",
"        DAGC; transduces contractile force",
"       </td>",
"       <td>",
"        300377",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        63, 64",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        TAZ/G4.5",
"       </td>",
"       <td>",
"        Tafazzin",
"       </td>",
"       <td>",
"        Unknown; causes Barth syndrome",
"       </td>",
"       <td>",
"        300394",
"       </td>",
"       <td>",
"        ?",
"       </td>",
"       <td>",
"        65, 66",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DAGC: dystrophin-associated glycoprotein complex.",
"     <br>",
"      * Genes ordered by the fraction of DCM probands carying mutations based upon primary and secondary reports; all are autosomal except as indicated.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       ? denotes estimate &lt;0.01 or inadequate data for estimate.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Kamisago M, Sharma SD, DePalma SR, et al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 2000; 343:1688.",
"       </li>",
"       <li>",
"        Daehmlow S, Erdmann J, Knueppel T, et al. Novel mutations in sarcomeric protein genes in dilated cardiomyopathy. Biochem Biophys Res Commun. 2002; 298:116-20.",
"       </li>",
"       <li>",
"        Villard E, Duboscq-Bidot L, Charron P, et al. Mutation screening in dilated cardiomyopathy: prominent role of the beta myosin heavy chain gene. Eur Heart J 2005; 26:794.",
"       </li>",
"       <li>",
"        Hershberger RE, Parks SB, Kushner JD, et al. Coding sequence mutations identified in MYH7, TNNT2, SCN5A, CSRP3, LBD3, and TCAP from 313 patients with familial or idiopathic dilated cardiomyopathy. Clin Translational Science 2008; 1:21.",
"       </li>",
"       <li>",
"        Carniel E, Taylor MR, Sinagra G, et al. Alpha-myosin heavy chain: a sarcomeric gene associated with dilated and hypertrophic phenotypes of cardiomyopathy. Circulation 2005; 112:54.",
"       </li>",
"       <li>",
"        Hershberger RE, Norton N, Morales A, et a. Coding sequence rare variants identified in MYBPC3, MYH6, TPM1, TNNC1, and TNNI3 from 312 patients with familial or idiopathic dilated cardiomyopathy. Circ Cardiovasc Genet 2010; 3:155.",
"       </li>",
"       <li>",
"        Duboscq-Bidot L, Xu P, Charron P, et al. Mutations in the Z-band protein myopalladin gene and idiopathic dilated cardiomyopathy. Cardiovasc Res 2008; 77:118.",
"       </li>",
"       <li>",
"        Hanson E, Jakobs P, Keegan H, et al. Cardiac troponin T lysine-210 deletion in a family with dilated cardiomyopathy. J Card Fail 2002; 8:28.",
"       </li>",
"       <li>",
"        Li D, Czernuszewicz GZ, Gonzalez O, et al. Novel cardiac troponin T mutation as a cause of familial dilated cardiomyopathy. Circulation 2001; 104:2188.",
"       </li>",
"       <li>",
"        Mogensen J, Murphy RT, Shaw T, et al. Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2004; 44:2033.",
"       </li>",
"       <li>",
"        Moller DV, Andersen PS, Hedley P, et al. The role of sarcomere gene mutations in patients with idiopathic dilated cardiomyopathy. Eur J Hum Genet 2009; 17:1241.",
"       </li>",
"       <li>",
"        Brauch KM, Karst ML, Herron KJ, et al. Mutations in ribonucleic acid binding protein gene cause familial dilated cardiomyopathy. J Am Coll Cardiol 2009; 54:930.",
"       </li>",
"       <li>",
"        Li D, Morales A, Gonzalez Quintana J, et al. Identification of novel mutations In RBM20 in patients with dilated cardiomyopathy. Clin Trans Sci 2010; 3:90.",
"       </li>",
"       <li>",
"        Taylor MR, Slavov D, Gajewski A, et al. Thymopoietin (lamina-associated polypeptide 2) gene mutation associated with dilated cardiomyopathy. Hum Mutat 2005; 26:566.",
"       </li>",
"       <li>",
"        Knoll R, Postel R, Wang J, et al. Laminin-alpha4 and integrin-linked kinase mutations cause human cardiomyopathy via simultaneous defects in cardiomyocytes and endothelial cells. Circulation 2007; 116:515.",
"       </li>",
"       <li>",
"        Olson TM, Illenberger S, Kishimoto NY, et al. Metavinculin mutations alter actin interaction in dilated cardiomyopathy. Circulation 2002; 105:431.",
"       </li>",
"       <li>",
"        Vatta M, Mohapatra B, Jimenez S, et al. Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. J Am Coll Cardiol 2003; 42:2014.",
"       </li>",
"       <li>",
"        Hayashi T, Arimura T, Itoh-Satoh M, et al. Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. J Am Coll Cardiol 2004; 44:2192.",
"       </li>",
"       <li>",
"        Li D, Parks SB, Kushner JD, et al. Mutations of presenilin genes in dilated cardiomyopathy and heart failure. Am J Hum Genet 2006; 79:1030.",
"       </li>",
"       <li>",
"        Mohapatra B, Jimenez S, Lin JH, et al. Mutations in the muscle LIM protein and alpha-actinin-2 genes in dilated cardiomyopathy and endocardial fibroelastosis. Mol Genet Metab 2003; 80:207.",
"       </li>",
"       <li>",
"        Inagaki N, Hayashi T, Arimura T, et al. Alpha B-crystallin mutation in dilated cardiomyopathy. Biochem Biophys Res Commun 2006; 342:379.",
"       </li>",
"       <li>",
"        Olson TM, Kishimoto NY, Whitby FG, Michels VV. Mutations that alter the surface charge of alpha-tropomyosin are associated with dilated cardiomyopathy. J Mol Cell Cardiol 2001; 33:723.",
"       </li>",
"       <li>",
"        Lakdawala NK, Dellefave L, Redwood CS, et al. Familial dilated cardiomyopathy caused by an alpha-tropomyosin mutation: the distinctive natural history of sarcomeric dilated cardiomyopathy. J Am Coll Cardiol 2010; 55:320.",
"       </li>",
"       <li>",
"        Bienengraeber M, Olson TM, Selivanov VA, et al. ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating. Nat Genet 2004; 36:382.",
"       </li>",
"       <li>",
"        Olson TM, Michels VV, Thibodeau SN, et al. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 1998; 280:750.",
"       </li>",
"       <li>",
"        Mayosa, B, Khogali, S, Zhang, B, Watkins, H. Cardiac and skeletal actin gene mutations are not a common cause of dilated cardiomyopathy. J Med Genet 1999; 36:796.",
"       </li>",
"       <li>",
"        Takai E, Akita H, Shiga N, et al. Mutational analysis of the cardiac actin gene in familial and sporadic dilated cardiomyopathy. Am J Med Genet 1999; 86:325.",
"       </li>",
"       <li>",
"        Tesson F, Sylvius N, Pilotto A, et al. Epidemiology of desmin and cardiac actin gene mutations in a european population of dilated cardiomyopathy. Eur Heart J 2000; 21:1872.",
"       </li>",
"       <li>",
"        Zolty R, Brodsky G, Perryman B, et al. Epidemiology of cardiac actin gene mutations in dilated cardiomyopathy. J Cardiac Failure 1999; 5:Supple 1:23.",
"       </li>",
"       <li>",
"        Taylor MR, Slavov D, Ku L, et al. Prevalence of desmin mutations in dilated cardiomyopathy. Circulation 2007; 115:1244.",
"       </li>",
"       <li>",
"        Arola AM, Sanchez X, Murphy RT, et al. Mutations in PDLIM3 and MYOZ1 encoding myocyte Z line proteins are infrequently found in idiopathic dilated cardiomyopathy. Mol Genet Metab 2007; 90:435.",
"       </li>",
"       <li>",
"        Murphy RT, Mogensen J, Shaw A, et al. Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy. Lancet 2004; 363:371.",
"       </li>",
"       <li>",
"        Schmitt JP, Kamisago M, Asahi M, et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 2003; 299:1410.",
"       </li>",
"       <li>",
"        Haghighi K, Kolokathis F, Pater L, et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest 2003; 111:869.",
"       </li>",
"       <li>",
"        DeWitt MM, MacLeod HM, Soliven B, McNally EM. Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy. J Am Coll Cardiol 2006; 48:1396.",
"       </li>",
"       <li>",
"        Medin M, Hermida-Prieto M, Monserrat L, et al. Mutational screening of phospholamban gene in hypertrophic and idiopathic dilated cardiomyopathy and functional study of the PLN -42 C&gt;G mutation. Eur J Heart Fail 2007; 9:37.",
"       </li>",
"       <li>",
"        Li D, Tapscoft T, Gonzalez O, et al. Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circ 1999; 100:461.",
"       </li>",
"       <li>",
"        Karkkainen S, Miettinen R, Tuomainen P, et al. A novel mutation, Arg71Thr, in the delta-sarcoglycan gene is associated with dilated cardiomyopathy. J Mol Med 2003; 15:15.",
"       </li>",
"       <li>",
"        Tsubata S, Bowles KR, Vatta M, et al. Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J Clin Invest 2000; 106:655.",
"       </li>",
"       <li>",
"        Sylvius N, Duboscq-Bidot L, Bouchier C, et al. Mutational analysis of the beta- and delta-sarcoglycan genes in a large number of patients with familial and sporadic dilated cardiomyopathy. Am J Med Genet 2003; 120A:8.",
"       </li>",
"       <li>",
"        Knoll R, Hoshijima M, Hoffman HM, et al. The Cardiac Mechanical Stretch Sensor Machinery Involves a Z Disc Complex that Is Defective in a Subset of Human Dilated Cardiomyopathy Cell 2002; 111:943.",
"       </li>",
"       <li>",
"        Gerull B, Gramlich M, Atherton J, et al. Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat Genet 2002; 14:14.",
"       </li>",
"       <li>",
"        Gerull B, Atherton J, Geupel A, et al. Identification of a novel frameshift mutation in the giant muscle filament titin in a large Australian family with dilated cardiomyopathy. J Mol Med 2006; 84:478.",
"       </li>",
"       <li>",
"        Schonberger J, Wang L, Shin JT, et al. Mutation in the transcriptional coactivator EYA4 causes dilated cardiomyopathy and sensorineural hearing loss. Nat Genet 2005; 37:418.",
"       </li>",
"       <li>",
"        Duboscq-Bidot L, Charron P, Ruppert V, et al. Mutations in the ANKRD1 gene encoding CARP are responsible for human dilated cardiomyopathy. Eur Heart J 2009; 30:2128.",
"       </li>",
"       <li>",
"        Purevjav E, Varela J, Morgado M, et al. Nebulette mutations are associated with dilated cardiomyopathy and endocardial fibroelastosis. J Am Coll Cardiol 2010; 56:1493.",
"       </li>",
"       <li>",
"        Fatkin D, MacRae C, Sasaki T, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 1999; 341:1715.",
"       </li>",
"       <li>",
"        Brodsky G, Muntoni F, Miocic S, et al. Lamin A/C gene mutation associated with dilated cardiomyopathy with variable skeletal muscle involvement. Circulation 2000; 101:473.",
"       </li>",
"       <li>",
"        Becane HM, Bonne G, Varnous S, et al. High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutation. Pacing Clin Electrophysiol 2000; 23:1661.",
"       </li>",
"       <li>",
"        Jakobs PM, Hanson E, Crispell KA, et al. Novel lamin A/C mutations in two families with dilated cardiomyopathy and conduction system disease. J Card Fail 2001; 7:249.",
"       </li>",
"       <li>",
"        Arbustini E, Pilotto A, Repetto A, et al. Autosomal dominant dilated cardiomyopathy with atrioventricular block: a lamin A/C defect-related disease. J Am Coll Cardiol 2002; 39:981.",
"       </li>",
"       <li>",
"        Hershberger RE, Hanson E, Jakobs PM, et al. A novel lamin A/C mutation in a family with dilated cardiomyopathy, prominent conduction system disease, and need for permanent pacemaker implantation. Am Heart J 2002; 144:1081.",
"       </li>",
"       <li>",
"        Taylor MR, Fain PR, Sinagra G, et al. Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. J Am Coll Cardiol 2003; 41:771.",
"       </li>",
"       <li>",
"        Sebillon P, Bouchier C, Bidot LD, et al. Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutations. J Med Genet 2003; 40:560.",
"       </li>",
"       <li>",
"        MacLeod HM, Culley MR, Huber JM, McNally EM. Lamin A/C truncation in dilated cardiomyopathy with conduction disease. BMC Med Genet 2003; 4:4.",
"       </li>",
"       <li>",
"        Sylvius N, Bilinska ZT, Veinot JP, et al. In vivo and in vitro examination of the functional significances of novel lamin gene mutations in heart failure patients. J Med Genet 2005; 42:639.",
"       </li>",
"       <li>",
"        Pethig K, Genschel J, Peters T, et al. LMNA mutations in cardiac transplant recipients. Cardiology 2005; 103:57.",
"       </li>",
"       <li>",
"        Karkkainen S, Reissell E, Helio T, et al. Novel mutations in the lamin A/C gene in heart transplant recipients with end stage dilated cardiomyopathy. Heart 2006; 92:524.",
"       </li>",
"       <li>",
"        Parks SB, Kushner JD, Nauman D, et al. Lamin A/C mutation analysis in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy. Am Heart J 2008; 156:161.",
"       </li>",
"       <li>",
"        Pasotti M, Klersy C, Pilotto A, et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol 2008; 52:1250.",
"       </li>",
"       <li>",
"        McNair WP, Ku L, Taylor MR, et al. SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia. Circulation 2004; 110:2163.",
"       </li>",
"       <li>",
"        Olson TM, Michels VV, Ballew JD,et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA. 2005; 293:447.",
"       </li>",
"       <li>",
"        Towbin JA, Hejtmancik JF, Brink P, et al. X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation 1993; 87:1854.",
"       </li>",
"       <li>",
"        Muntoni F, Cau M, Ganau A, et al. Brief report: Deletion of the dystrophin muscle-promoter region associated with x-linked dilated cardiomyopathy. N Engl J Med 1993; 329:921.",
"       </li>",
"       <li>",
"        D'Adamo P, Fassone L, Gedeon A, et al. The x-linked gene G4.5 is responsible for different infantile dilated cardiomyopathies. Am J Hum Genet 1997; 61:862.",
"       </li>",
"       <li>",
"        Bione S, D'Adamo P, Maestrini E, et al. A novel X-linked gene, G4.5, is responsible for Barth syndrome. Nat Genet 1996; 12:385.",
"       </li>",
"       <li>",
"        Herman DS, Lam L, Taylor MRG, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med 2012; 36:619.",
"       </li>",
"      </ol>",
"      Reproduced&nbsp;with permission from: Hershberger RE, Morales MS, Siegfried MS. Clinical and genetic issues in dilated cardiomyopathy: A review for genetics professionals. Genet Med 2010; 12:655. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins. Additional data added for this publication from Reference 67.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_58_5025=[""].join("\n");
var outline_f4_58_5025=null;
var title_f4_58_5026="Epidermolysis bullosa acquisita histopathology";
var content_f4_58_5026=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Epidermolysis bullosa acquisita",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A pauci-inflammatory subepidermal blister, dermal fibroplasia, and milium formation are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_58_5026=[""].join("\n");
var outline_f4_58_5026=null;
var title_f4_58_5027="Samarium Sm-153 lexidronam: Drug information";
var content_f4_58_5027=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Samarium Sm-153 lexidronam: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/62/23523?source=see_link\">",
"    see \"Samarium Sm-153 lexidronam: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F16565519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Quadramet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13185988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Radiopharmaceutical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13186086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Palliation of osteoblastic metastatic bone lesions:",
"     </b>",
"     I.V.: 1 mCi/kg (37 MBq/kg)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F16565520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Quadramet&reg;: 50 mCi (1850 MBq)/mL (3 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F16565538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13204464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Give 500 mL of fluids (I.V. or orally) prior to administration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13186071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of pain associated with osteoblastic metastatic bone lesions that demonstrate increased localization on radionuclide bone scans",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13255272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13186088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Hematologic: Thrombocytopenia (69%), leukopenia (59%), anemia (41%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, hypertension, stroke",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Ecchymosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bone pain, spinal cord compression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis, epistaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13186072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Known hypersensitivity to ethylenediaminetetramethylenephosphonic acid (EDTMP) or similar phosphonate compounds",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13186073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of individuals who have received training in the handling of radioactive materials and who are authorized by the applicable regulatory authority.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bone marrow suppression: Can cause myelosuppression (leukopenia, thrombocytopenia, and anemia); consider current hematologic status and history of myelosuppressive response to other myelotoxic agents prior to therapy. Evaluate the risk:benefit when combining with other myelotoxic therapies. Avoid myelosuppressive therapies for 4-8 weeks before and for 12 weeks after samarium Sm 153 lexidronam.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Disseminated intravascular coagulation (DIC): Active DIC may be a risk factor for severe thrombocytopenia following therapy; deaths have occurred in patients with DIC receiving &beta;-emitting radiopharmaceuticals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Incontinence: Incontinent patients may require urinary catheterization to reduce the risk of radioactive contamination of clothes or bed linens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pregnancy: May cause fetal harm if administered during pregnancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Spinal cord compression (SCC): Not indicated for the treatment of SCC; SCC has been reported in patients receiving samarium Sm 153 lexidronam.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13186079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13186080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not been conducted. There are no adequate and well-controlled studies in pregnant women. Radiopharmaceuticals have the potential to cause fetal harm. Women of childbearing potential should avoid becoming pregnant during or soon after treatment. Both males and females should use effective contraception following treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13186081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13186082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is unknown whether or not samarium Sm 153 lexidronam is excreted in breast milk; however, based on assumptions and calculations, the patient must be instructed to cease breast-feeding (U.S. Nuclear Regulatory Commission, 1977).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Quadramet Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1850 mbq/ml (3 mL): $8965.20",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Henkin RE, Hartford AC, Del Rowe JD, et al, \"ACR&ndash;ASTRO Practice Guideline for the Performance of Therapy with Unsealed Radiopharmaceutical Sources,\" 2010. Available at file://www.acr.org/secondarymainmenucategories/quality_safety/guidelines/nuc_med/unsealed_radiopharmaceuticals.aspx . Last accessed August 26, 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silberstein EB, Buscombe JR, McEwan A, et al, \"Society of Nuclear Medicine Procedure Guideline for Palliative Treatment of Painful Bone Metastases,\" 2003. Available at file://interactive.snm.org/docs/pg_ch25_0403.pdf. Last accessed August 26, 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Nuclear Regulatory Commission, \"Regulatory Guide 8.39. Release of Patients Administered Radioactive Materials,\" 1977.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16804 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-5B3EA195B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_58_5027=[""].join("\n");
var outline_f4_58_5027=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16565519\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13185988\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13186086\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16565520\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16565538\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13204464\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13186071\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13255272\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13186088\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13186072\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13186073\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13186079\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13186080\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13186081\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13186082\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322914\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16804\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16804|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/62/23523?source=related_link\">",
"      Samarium Sm-153 lexidronam: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_58_5028="Umbilical hernia repair";
var content_f4_58_5028=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F53945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F53945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Umbilical hernia repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 573px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Repair of an umbilical hernia. A) Diagram of longitudinal section through the hernia. B) Subumbilical \"smile\" incision. The hernial sac is excised. C) Waistcoat type of closure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mulholland, MW, Lillemoe, KD. Greenfield's Surgery: Scientific Principles And Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_58_5028=[""].join("\n");
var outline_f4_58_5028=null;
var title_f4_58_5029="Ultrasound femoral vessels";
var content_f4_58_5029=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound of normal femoral vessels",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 463px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse ultrasound images of the right groin demonstrate the normal vascular orientation, with the common femoral vein (blue arrow) medial to the common femoral artery (red arrow). Nearby muscles are also seen, including the sartorius (S), rectus femoris (RF), and pectineus (P). A) Image of the right groin without compression shows the patent common femoral artery and vein. B) Image of the right groin with compression shows collapse of the common femoral vein while the artery remains patent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lauren W Averill, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_58_5029=[""].join("\n");
var outline_f4_58_5029=null;
var title_f4_58_5030="Rhizopus hyphae lung tissue";
var content_f4_58_5030=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rhizopus arrhizus hyphae in lung tissue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyphae in lung tissue, H &amp; E stain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of www.doctorfungus.org. Copyright &copy;2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_58_5030=[""].join("\n");
var outline_f4_58_5030=null;
var title_f4_58_5031="Eplerenone: Drug information";
var content_f4_58_5031=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Eplerenone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/49/23316?source=see_link\">",
"    see \"Eplerenone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Inspra&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F15245732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Inspra&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F165711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diuretic, Potassium Sparing;",
"     </li>",
"     <li>",
"      Selective Aldosterone Blocker",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F165694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 50 mg once daily; may increase to 50 mg twice daily if response is not adequate; may take up to 4 weeks for full therapeutic response. Doses &gt;100 mg/day are associated with increased risk of hyperkalemia and no greater therapeutic effect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dose modification during concurrent use with",
"      <b>",
"       moderate",
"      </b>",
"      CYP3A4 inhibitors:",
"     </i>",
"     Initial: 25 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heart failure (post-MI):",
"     </b>",
"     Oral: Initial: 25 mg once daily; dosage goal: Titrate to 50 mg once daily within 4 weeks, as tolerated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment per serum potassium concentrations for HF (post-MI):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      &lt;5 mEq/L:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Increase dose from 25 mg every other day to 25 mg daily",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Increase dose from 25 mg daily to 50 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      5-5.4 mEq/L:",
"     </i>",
"     No adjustment needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      5.5-5.9 mEq/L:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Decrease dose from 50 mg daily to 25 mg daily",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Decrease dose from 25 mg daily to 25 mg every other day",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Modify dose from 25 mg every other day to withhold medication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      &ge;6 mEq/L:",
"     </i>",
"     Withhold medication until potassium &lt;5.5 mEq/L, then restart at 25 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Chronic HF (NYHA class II) or HF (post-MI):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     eGFR &ge;50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     and potassium &le;5 mEq/L: Initial: 25 mg once daily; may increase within 4 weeks as tolerated to a target dose of 50 mg once daily (maximum dose).",
"     <b>",
"      Note:",
"     </b>",
"     Treatment following MI should be initiated 3-14 days after MI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Concurrent use with",
"      <b>",
"       mild-to-moderate",
"      </b>",
"      CYP3A4 inhibitors:",
"     </i>",
"     Maximum dose: 25 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     eGFR 30-49 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     and potassium &le;5 mEq/L: Initial: 25 mg every other day; may increase within 4 weeks as tolerated to a target dose of 25 mg once daily (maximum dose).",
"     <b>",
"      Note:",
"     </b>",
"     Treatment following MI should be initiated 3-14 days after MI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Concurrent use with",
"      <b>",
"       mild-to-moderate",
"      </b>",
"      CYP3A4 inhibitors:",
"     </i>",
"     Avoid concurrent use  (target dose &lt;25 mg once daily has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment (after initiation) per serum potassium concentrations:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      &lt;5 mEq/L:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Current dose is 25 mg every other day: Increase to 25 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Current dose is 25 mg daily and eGFR &ge;50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     or",
"     <b>",
"      not taking",
"     </b>",
"     concurrent mild-to-moderate CYP3A4 inhibitor: Increase to 50 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Current dose is 25 mg daily and eGFR 30-49 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     or",
"     <b>",
"      if taking",
"     </b>",
"     concurrent mild-to-moderate CYP3A4 inhibitor: Do not increase dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      5-5.4 mEq/L:",
"     </i>",
"     No adjustment needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      5.5-5.9 mEq/L:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Current dose is 50 mg daily: Decrease to 25 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Current dose is 25 mg daily: Decrease to 25 mg every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Current dose is 25 mg every other day: Withhold further doses; reinitiate only if potassium &lt;5 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      &ge;6 mEq/L:",
"     </i>",
"     Withhold further doses until potassium &lt;5 mEq/L, then may temporarily resume therapy at 25 mg every other day (dose efficacy has not been established); reassess potassium levels in 1 week and if within acceptable limits, increase dose to 25 mg once daily; reassess potassium levels again in 1 week to determine whether therapy should be continued or interrupted.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F165695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F165696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hypertension: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute or serum creatinine &gt;2 mg/dL (males) or &gt;1.8 mg/dL (females): Use is contraindicated; risk of hyperkalemia increases with declining renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HF (post-MI):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-50 mL/minute or serum creatinine &gt;2 mg/dL (males) or &gt;1.8 mg/dL (females): No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     eGFR &ge;50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : No dosage adjustment necessary unless receiving concurrent mild-to-moderate CYP3A4 inhibitor, then maximum dose is 25 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     eGFR 30-49 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Initial: 25 mg every other day; titrate to 25 mg once daily (maximum dose) within 4 weeks, as tolerated. Avoid concurrent use with mild-to-moderate CYP3A4 inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     eGFR &le;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F165697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mild-to-moderate impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mild-to-moderate impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe impairment: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F165669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Inspra&trade;: 25 mg, 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F165656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F165672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F165671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     U.S. labeling: Treatment of hypertension (may be used alone or in combination with other antihypertensive agents); treatment of heart failure (HF) (LVEF &le;40%) following acute MI",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Canadian labeling: Treatment of NYHA class II chronic heart failure (HF) with left ventricular systolic dysfunction; treatment of HF following acute MI",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F165718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Inspra&trade; may be confused with Spiriva&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F165709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Endocrine &amp; metabolic: Hyperkalemia ([HF post-MI: K &gt;5.5 mEq/L: 16%; K &ge;6 mEq/L: 6%] [HTN: K &gt;5.5 mEq/L at doses &le;200 mg: &le;1%; dose of 400 mg: 9%]), hypertriglyceridemia (1% to 15%, dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (3%), fatigue (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyponatremia (2%, dose related), breast pain (males &lt;1% to 1%), gynecomastia (males &lt;1% to 1%), hypercholesterolemia (&lt;1% to 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (2%), abdominal pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Abnormal vaginal bleeding (&lt;1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Creatinine increased (HF post-MI: 6%), albuminuria (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1%, postmarketing, and/or case reports: Angioneurotic edema, BUN increased, liver function tests increased, rash, uric acid increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F165675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     U.S. labeling: Serum potassium &gt;5.5 mEq/L at initiation; Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute; concomitant use of strong CYP3A4 inhibitors (see Drug Interactions for details)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     The following additional contraindications apply to patients with hypertension: Type 2 diabetes mellitus (noninsulin dependent, NIDDM) with microalbuminuria; serum creatinine &gt;2.0 mg/dL in males or &gt;1.8 mg/dL in females; Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute; concomitant use with potassium supplements or potassium-sparing diuretics",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Canadian labeling: Hypersensitivity to eplerenone or any component of the formulation; serum potassium &gt;5 mEq/L at initiation; severe hepatic impairment (Child-Pugh class C); severe renal impairment (eGFR &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ); clinically significant hyperkalemia; concomitant use with potassium supplements, potassium-sparing diuretics or strong CYP3A4 inhibitors",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F165659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Monitor closely for hyperkalemia; increases in serum potassium were dose related during clinical trials and rates of hyperkalemia also increased with declining renal function. Dose reduction or interruption of therapy may be necessary with development of hyperkalemia. Use is contraindicated in patients with potassium &gt;5.5 mEq/L (U.S. labeling) or &gt;5 mEq/L (Canadian labeling) at initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with heart failure post-MI with diabetes (especially if patient has proteinuria); risk of hyperkalemia is increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment; safety and efficacy have not been established. Canadian labeling contraindicates use in severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Risk of hyperkalemia is increased with declining renal function. Use with caution in patients with mild renal impairment; contraindicated with moderate-severe impairment (hypertension: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute; heart failure post-MI: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute). Canadian labeling contraindicates use in all patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Dosage adjustment needed for patients on moderate CYP3A4 inhibitors (U.S. labeling) or mild-to-moderate inhibitors (Canadian labeling).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F165705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F165663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Eplerenone may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Eplerenone may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Eplerenone.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Eplerenone. Canagliflozin may enhance the hypotensive effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Eplerenone may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Eplerenone. Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Eplerenone. Management: Reduce the starting dose of eplerenone to 25 mg/day; monitor patients closely for increased eplerenone effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Eplerenone may increase the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Eplerenone.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitrofurantoin: May enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: Eplerenone may enhance the hyperkalemic effect of Potassium Salts.  Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Eplerenone may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.  Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Eplerenone may enhance the hyperkalemic effect of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F165688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Grapefruit juice increases eplerenone AUC ~25%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease levels of eplerenone. Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse (may have increased antihypertensive effect). Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice (may diminish the antihypertensive effect).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F165665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F165678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No teratogenic effects were seen in animal reproduction studies, however, there are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the potential benefit to the mother outweighs the possible risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F165701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F165679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food. Do not use salt substitutes containing potassium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F165677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Eplerenone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (30): $123.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $123.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Inspra Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (90): $559.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $186.44",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F165667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; serum potassium (prior to therapy, within the first week, 1 month after start of treatment or dose adjustment, then periodically as clinically indicated); additionally, check serum potassium in 3-7 days after initiating concurrent therapy with moderate CYP3A4 inhibitor; serum creatinine",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Elecor (ES);",
"     </li>",
"     <li>",
"      Eptus (IN);",
"     </li>",
"     <li>",
"      Inspra (AT, AU, BE, BG, CH, CZ, DE, DK, EE, FI, FR, GB, GR, HK, HN, IE, IL, NL, NO, NZ, PL, PT, SE, SG, TW);",
"     </li>",
"     <li>",
"      Inspra IC (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F165658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aldosterone, a mineralocorticoid, increases blood pressure primarily by inducing sodium and water retention. Overexpression of aldosterone is thought to contribute to myocardial fibrosis (especially following myocardial infarction) and vascular fibrosis. Mineralocorticoid receptors are located in the kidney, heart, blood vessels, and brain. Eplerenone selectively blocks mineralocorticoid receptors reducing blood pressure in a dose-dependent manner and appears to prevent myocardial and vascular fibrosis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F165674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 43-90 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~50%; primarily to alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoproteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic via CYP3A4; metabolites inactive",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 69%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: ~1.5 hours; may take up to 4 weeks for full antihypertensive effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~67%); feces (32%); &lt;5% as unchanged drug in urine and feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5031/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5031/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5031/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pitt B, Remme W, Zannad F, et al, &ldquo;Eplerenone, A Selective Aldosterone Blocker, in Patients With Left Ventricular Dysfunction After Myocardial Infarction,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(14):1309-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5031/abstract-text/12668699/pubmed\" id=\"12668699\" target=\"_blank\">",
"        12668699",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pitt B, Zannad F, Remme WJ, et al, &ldquo;The Effect of Spironolactone on Morbidity and Mortality in Patients With Severe Heart Failure. Randomized Aldactone Evaluation Study Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 341(10):709-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5031/abstract-text/10471456/pubmed\" id=\"10471456\" target=\"_blank\">",
"        10471456",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5031/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zannad F, McMurray JJ, Krum H, et al, &ldquo;Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 4(1):11-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5031/abstract-text/21073363/pubmed\" id=\"21073363\" target=\"_blank\">",
"        21073363",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8789 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-EFEE8658EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_58_5031=[""].join("\n");
var outline_f4_58_5031=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165691\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245732\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165711\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165694\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165695\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165696\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165697\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165669\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165656\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165672\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165671\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165718\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165709\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165675\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165659\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165705\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165663\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165688\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165665\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165678\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165701\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165679\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165677\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165667\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539853\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165658\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165674\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8789\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8789|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/49/23316?source=related_link\">",
"      Eplerenone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_58_5032="Psychotherapy for posttraumatic stress disorder";
var content_f4_58_5032=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Psychotherapy for posttraumatic stress disorder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/58/5032/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/58/5032/contributors\">",
"     Barbara O Rothbaum, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/58/5032/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/58/5032/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/58/5032/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/58/5032/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/58/5032/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1118664153\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posttraumatic stress disorder (PTSD) is a severe, often chronic and disabling anxiety disorder, which develops in some persons following exposure to a traumatic event involving actual or threatened injury to themselves or others. PTSD is characterized by intrusive thoughts, nightmares and flashbacks of past traumatic events, avoidance of reminders of trauma, hypervigilance, and sleep disturbance, all of which lead to considerable social, occupational, and interpersonal dysfunction.",
"   </p>",
"   <p>",
"    Treatments for PTSD include medications and psychotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Among the psychotherapies, clinical trials most strongly support the use of various types of trauma-focused cognitive behavioral therapy (CBT). CBT typically includes components of cognitive therapy, exposure, and coping skills training.",
"   </p>",
"   <p>",
"    This topic addresses psychotherapy for PTSD. The epidemiology, pathophysiology, clinical manifestations, diagnosis, and pharmacotherapy for PTSD are discussed separately. Dissociative aspects of PTSD are also discussed separately. The epidemiology, pathophysiology, clinical manifestations, diagnosis, and treatment of acute stress disorder are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=see_link\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=see_link\">",
"     \"Pharmacotherapy for posttraumatic stress disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/32/522?source=see_link\">",
"     \"Dissociative aspects of posttraumatic stress disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7080?source=see_link\">",
"     \"Acute stress disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24197?source=see_link\">",
"     \"Treatment of acute stress disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118664160\">",
"    <span class=\"h1\">",
"     COGNITIVE AND BEHAVIORAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive and behavioral therapies used to treat PTSD include exposure therapy, cognitive therapy, and various combinations of these modalities, often with other components. These modalities are sometimes described collectively as trauma-focused CBT if they specifically focus on the traumatic material. Cognitive approaches help patients to correct erroneous cognitions, while behavioral approaches aim to decrease symptoms through exposure to reminders of the traumatic event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118664169\">",
"    <span class=\"h2\">",
"     Theory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective studies indicate that PTSD symptoms are almost universal in the immediate aftermath of trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/6\">",
"     6",
"    </a>",
"    ]. The majority of individuals have symptoms of re-experiencing, avoidance, and hyperarousal following a severely traumatic event. For most individuals these symptoms steadily resolve over time, while those who meet diagnostic criteria for PTSD continue to experience the symptoms. PTSD can thus be viewed as a failure of recovery caused in part by a failure of fear extinction following trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals with PTSD are hypothesized to develop cognitive and behavioral avoidance strategies in an attempt to avoid distressing emotional reactions. The presence of these extensive avoidance responses can interfere with the extinction of fear by limiting the amount of exposure to realistically safe reminders of the traumatic event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118664176\">",
"    <span class=\"h3\">",
"     Basic science of conditioned fear",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the pairing of an aversive (unconditioned) stimulus (ie, the traumatic event) to a neutral (conditioned) stimulus (ie, stimuli associated with the traumatic event, including recollection of it), a conditioned fear response is established. If the neutral (conditioned) stimulus is then repeatedly presented in the absence of the aversive (unconditioned) stimulus (ie, exposure to stimuli associated with the traumatic event), a procedure known as extinction training, the result is an inhibition of the conditioned fear response to the neutral (conditioned) stimulus.",
"   </p>",
"   <p>",
"    Emotional processing theory holds that PTSD emerges due to the development of a fear network in memory that elicits escape and avoidance behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. This theory proposes that effective therapy involves correcting the pathological elements of the fear memory, and that this corrective process is the essence of emotional processing.",
"   </p>",
"   <p>",
"    Two conditions have been proposed as necessary for emotional processing of the traumatic incident to occur. First, the fear memory must be activated. Second, new, corrective information must be provided that includes elements incompatible with the existing pathological components. Exposure procedures consist of helping the patient to confront trauma-related information in a therapeutic manner in order to activate the trauma memory. This activation provides an opportunity for the patient to integrate corrective information and modify pathological components of the trauma memory. Corrective information comes in the form of decreased fear responses while still in the presence of trauma reminders and lack of a recurrence of the trauma even when exposed to trauma reminders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118664183\">",
"    <span class=\"h2\">",
"     Cognitive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The application of cognitive therapy to PTSD is based on the theory that the meanings that we impose on events contribute to emotional states, and therefore changing how we think about them can reduce PTSD symptoms and improve wellbeing.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    In the cognitive therapies, patients are assisted in thinking about the traumatic event and themselves more realistically. Socratic questioning is used to elicit information and challenge the patient&rsquo;s maladaptive beliefs.",
"   </p>",
"   <p>",
"    An example can illustrate the use of cognitive therapy for PTSD. A woman raped by a home intruder wrongly&nbsp;blamed herself. The therapist led the woman through a series of questions about the event, establishing through her answers that her actions were reasonable, that she had not done anything to bring on the event and that she could not have prevented it. She was then asked, if her sister or her daughter behaved in the same way under the same circumstances, would she think they were to blame? Allowing the woman to generate the information in this discussion and then to reevaluate her perceptions was successful in changing her self-blaming beliefs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118664190\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systematic reviews of cognitive therapy have come to different conclusions regarding effectiveness of cognitive therapy for PTSD, most positive but others finding inadequate evidence to support its efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. These reviews use different definitions of what constitutes cognitive therapy and different inclusion criteria in selecting randomized trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118664197\">",
"    <span class=\"h2\">",
"     Exposure therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure therapy assists patients in confronting their feared memories and situations in a therapeutic manner. Reexperiencing the trauma through exposure allows it to be emotionally processed so that it can become less painful [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. By repeatedly confronting traumatic memories or safe reminders of a traumatic experience, the individual can experience them safely, repeatedly if needed, until they no longer elicit such strong emotions and can see that they are not dangerous. (See",
"    <a class=\"local\" href=\"#H1118664176\">",
"     'Basic science of conditioned fear'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Many patients with PTSD mistakenly view remembering or processing the trauma as dangerous",
"    <strong>",
"     &mdash;",
"    </strong>",
"    probably because it is distressing",
"    <strong>",
"     &mdash;",
"    </strong>",
"    therefore they devote much effort to avoiding thinking about it. Reexperiencing the trauma through exposure serves to disconfirm this mistaken belief and allows them to experience decreasing levels of distress while still remembering what happened.",
"   </p>",
"   <p>",
"    Exposure therapy programs for PTSD typically incorporate the patient&rsquo;s recall of the traumatic event and confrontation with real-life, safe situations that remind the patient of the event, called &ldquo;in vivo exposure&rdquo;. An example of real-life exposure would be the return to the scene of an accident by a person who experienced a motor vehicle accident or driving the same car. Traumatic events can be reexperienced through verbal description, writing, or other means.",
"   </p>",
"   <p>",
"    Following the imaginal or virtual reality exposure portion of a session, it is important for the therapist and the patient to discuss material that emerged during the exposure. The discussion, or processing, often centers on the patient&rsquo;s emotional response to the exposure, for example, making explicit that by going through the memory three times, his distress decreased and he was able to remember more. This is also the time for the therapist to use Socratic questioning to challenge maladaptive thoughts the patient may hold, including beliefs related to guilt, blame, and responsibility.",
"   </p>",
"   <p>",
"    Exposure therapy programs often include homework exercises making use of &ldquo;imaginal exposure&rdquo;. In one common approach, a tape recording is made during a session of the patient describing the traumatic event aloud. Between sessions, the patient practices exposure at home, listening to the tape and further processing the traumatic material.",
"   </p>",
"   <p>",
"    As an example, prolonged exposure therapy is a specific exposure therapy program developed for PTSD. It consists of breathing retraining, education about common reactions to trauma, imaginal exposure to the trauma memory, processing of the traumatic material, and in vivo exposure to trauma reminders [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/10\">",
"     10",
"    </a>",
"    ]. Prolonged exposure is usually delivered in 9 to 12 weekly or twice weekly, 90 minute sessions, but can be shorter or longer based on the patient's needs and response. A table summarizes a typical course of prolonged exposure (",
"    <a class=\"graphic graphic_table graphicRef60594 \" href=\"UTD.htm?6/39/6781\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A more recently developed method for providing exposure therapy is through virtual reality. Virtual reality exposure therapy uses a head-mounted computer display to present the PTSD patient with visual, auditory, tactile, and other sensory material that stimulate traumatic memories and affective response (",
"    <a class=\"graphic graphic_picture graphicRef59083 \" href=\"UTD.htm?29/33/30225\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/11\">",
"     11",
"    </a>",
"    ]. Virtual reality exposure has been used to treat PTSD among soldiers and veterans exposed to combat, survivors of catastrophic disasters, and in the aftermath of serious motor vehicle accidents [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/12-15\">",
"     12-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118664204\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure therapy is an effective treatment for PTSD. A systematic review identified 23 randomized trials of exposure therapy for PTSD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/1\">",
"     1",
"    </a>",
"    ]. The trials studied exposure either individually or combined with other interventions, typically in comparison to waiting list status or receiving usual care. Seven of them were judged to be without major methodologic limitations. All seven found that exposure therapy reduced PTSD symptoms. Overall, the degree of improvement was clinically significant. Evidence of efficacy has been demonstrated in populations experiencing multiple types of trauma, though the evidence in military veterans is less consistent than for other groups [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a randomized trial of 277 women with largely chronic PTSD resulting from a mix of traumatic events, including sexual assault and military combat, compared prolonged exposure to present-centered therapy, a supportive intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/16\">",
"     16",
"    </a>",
"    ]. The group receiving prolonged exposure experienced a greater reduction of PTSD symptoms (25 versus 17 points on the Clinician-Administered PTSD Scale) and was more likely to no longer meet diagnostic criteria for PTSD (41 versus 28 percent) compared to the group receiving present-centered therapy. Prolonged exposure continued to show greater benefit three months following treatment.",
"   </p>",
"   <p>",
"    There are no published randomized trials of virtual reality exposure (VRE) for PTSD. Case series and uncontrolled trials suggest that VRE may be an effective treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/12,13,17-19\">",
"     12,13,17-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118664211\">",
"    <span class=\"h2\">",
"     Cognitive behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;CBT for PTSD includes both cognitive and behavioral components. It can also include additional approaches such as education and coping skills training. Specific programs of trauma-focused CBT vary in their composition. Trials have mostly tested individual CBT in PTSD, but a cognitive-behavioral couple therapy has been tested. (See",
"    <a class=\"local\" href=\"#H324030410\">",
"     'Couples therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As an example, cognitive processing therapy (CPT), a widely used therapy for PTSD, is principally a cognitive therapy, though it includes exposure to memories of the trauma. The exposure component consists of writing a detailed account of the trauma and reading it in the presence of the therapist and at home. CPT examines thoughts and feelings that emerge during the exposure exercise and provides training to challenge problematic beliefs about safety, trust, power, control, esteem, and intimacy. Individuals are taught to challenge faulty assumptions and self-statements and to modify maladaptive thoughts and over-generalized beliefs. CPT is used by the United States Veterans Administration to treat military veterans with PTSD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118664218\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a meta-analysis of 14 randomized trials involving 658 patients with PTSD, trauma-focused CBT led to greater reduction in PTSD symptoms than usual care [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/20\">",
"     20",
"    </a>",
"    ]. Despite the variability among CBT programs, studies comparing components individually or in different combinations have not found them to be consistently associated with differential outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/21-24\">",
"     21-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, 171 women with PTSD resulting from sexual assault were randomly assigned to either cognitive processing therapy, prolonged exposure, or a waiting-control group [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/25\">",
"     25",
"    </a>",
"    ]. Treatment consisted of 12 sessions conducted twice weekly for 60 to 90 minutes. The therapies were equally effective in reducing PTSD symptoms, and both were substantially more effective than the control intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H324030410\">",
"    <span class=\"h4\">",
"     Couples therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A trial tested a manual-based cognitive-behavioral conjoint therapy for individuals with PTSD and their partners [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/26\">",
"     26",
"    </a>",
"    ]. Forty couples (both heterosexual and same-sex) were randomly assigned to receive the 15-session couples therapy or to a waitlist control. At the end of the trial, participants receiving the couples therapy experienced a greater reduction in PTSD symptom severity and more improvement in intimate relationship satisfaction, compared to the control group. Treatment effects were maintained at three-month follow up. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=see_link&amp;anchor=H12#H12\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\", section on 'Course'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118664225\">",
"    <span class=\"h2\">",
"     Eye movement desensitization and reprocessing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eye movement desensitization and reprocessing (EMDR) is a form of CBT that incorporates saccadic eye movements during exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/27\">",
"     27",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    The technique involves the patient's imagining a scene from the trauma, focusing on the accompanying cognition and arousal, while the therapist moves two fingers across the patient's visual field and instructs the patient to track the fingers. The sequence is repeated until anxiety decreases, at which point the patient is instructed to generate a more adaptive thought. An example of a thought initially associated with the traumatic image might include, &ldquo;I&rsquo;m going to die,&rdquo; while the more adaptive thought might end up as, &ldquo;I made it through. It&rsquo;s in the past.&rdquo;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5497578\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most, but not all, systematic reviews and meta-analyses have concluded that EMDR is an efficacious treatment for PTSD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/1-4,20,28,29\">",
"     1-4,20,28,29",
"    </a>",
"    ]. A metaanalysis of five randomized trials with a total of 162 patients found EMDR reduced PTSD symptoms more than usual care or waiting list status (SMD=-1.51, 95% CI, -1.87 to -1.15) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/20\">",
"     20",
"    </a>",
"    ]. Several major practice guidelines but not all have similarly concluded that EMDR is efficacious for PTSD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/1,3,4,20\">",
"     1,3,4,20",
"    </a>",
"    ]. Some researchers have suggested that exposure is the effective component of EMDR, and eye movements may not be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/1\">",
"     1",
"    </a>",
"    ], but this hypothesis requires further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118664232\">",
"    <span class=\"h2\">",
"     Coping skills training",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of behavioral techniques are used for PTSD by therapists of all types. In contrast to the therapies above, these interventions do not focus on the patient's trauma. Usually one of several components of a therapy, evidence is lacking to suggest that these techniques are helpful to treat PTSD by themselves.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Role playing",
"     </li>",
"     <li>",
"      Assertiveness training",
"     </li>",
"     <li>",
"      Stress management",
"     </li>",
"     <li>",
"      Relaxation exercises",
"     </li>",
"     <li>",
"      Biofeedback, eg, using electromyography, heart rate, or respiration rate",
"     </li>",
"     <li>",
"      Teaching sleep hygiene",
"     </li>",
"     <li>",
"      Recommending exercise",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118664239\">",
"    <span class=\"h1\">",
"     PSYCHODYNAMIC PSYCHOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychodynamic therapy in the treatment of PTSD focuses on improving ego strength and capacity for interpersonal relatedness. Existing evidence is insufficient to evaluate the efficacy of psychodynamic therapy for PTSD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/1,11,20\">",
"     1,11,20",
"    </a>",
"    ]. Only one randomized trial has been conducted, lacking a non-treatment control, which found that patients receiving psychodynamic therapy showed rates of improvement similar to patients receiving hypnosis or systematic desensitization [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118664246\">",
"    <span class=\"h1\">",
"     ECLECTIC PSYCHOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In surveys of mental health clinicians in the US and Canada, a majority of clinicians (psychiatrists, psychologists, social workers, and others) identified themselves as practicing an eclectic or integrative form of psychotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Eclectic and integrative therapists draw concepts and techniques from a variety of different types of therapy, including dynamic, cognitive, and behavioral approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/33\">",
"     33",
"    </a>",
"    ]. These approaches vary by therapist, and their efficacy for PTSD has not been studied systematically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118664276\">",
"    <span class=\"h1\">",
"     TREATMENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on our clinical experience, we suggest first-line treatment of PTSD with an evidence based psychotherapy rather than medication. Evidence-based psychotherapies for PTSD include exposure therapy (eg, prolonged exposure), a combination of exposure and a cognitive therapy (eg, cognitive processing therapy), or with eye movement desensitization and reprocessing (EMDR). Trials have found these therapies to decrease PTSD symptoms compared to control conditions. There is an absence of clinical trials comparing these therapies to medication for PTSD. (See",
"    <a class=\"local\" href=\"#H1118664197\">",
"     'Exposure therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1118664211\">",
"     'Cognitive behavioral therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1118664225\">",
"     'Eye movement desensitization and reprocessing'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=see_link&amp;anchor=H5614755#H5614755\">",
"     \"Pharmacotherapy for posttraumatic stress disorder\", section on 'Comparing pharmacotherapy and psychotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patient presentation can be influential in selecting among types of psychotherapy. If the patient presents with extreme fear and avoidance, an exposure technique will likely be recommended. If the patient presents with extreme guilt and trust issues, cognitive therapy would be recommended. For highly avoidant patients who are difficult to engage, virtual reality exposure could be added where available, as its evocative nature renders it more difficult to avoid.",
"   </p>",
"   <p>",
"    If the patient's clinical presentation does not emphasize one of these symptom clusters, then therapy availability and patient preference typically determine type of treatment.",
"   </p>",
"   <p>",
"    Among patients who have not improved after eight or more sessions with a particular approach, the clinician may want to consider another evidence-based treatment (eg, a shift from exposure therapy to cognitive therapy or to pharmacotherapy). A stepped, symptom-driven process of selecting among types of therapies for PTSD has not been tested in clinical trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=see_link\">",
"     \"Pharmacotherapy for posttraumatic stress disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cognitive and behavioral therapies require specific training to be applied to PTSD patients. Cognitive processing therapy and prolonged exposure have detailed therapist and patient manuals to guide treatment. The techniques are taught and practiced with experts in two to four day workshops. We recommend that clinicians receive supervision for one to two cases after training. Practitioners from all clinical disciplines (eg, psychologists, psychiatrists, social workers) have been trained in these therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17273983\">",
"    <span class=\"h1\">",
"     COMPARING PSYCHOTHERAPY AND PSYCHOPHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials comparing psychotherapy to medication for PTSD. Patients with PTSD were included in an early intervention trial comparing CBT and an SSRI to prevent development of chronic PTSD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/34\">",
"     34",
"    </a>",
"    ], but results of the study did not distinguish between patients who had experienced PTSD symptoms for more than 30 days and those who did not. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=see_link&amp;anchor=H5614776#H5614776\">",
"     \"Pharmacotherapy for posttraumatic stress disorder\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15627796\">",
"    <span class=\"h1\">",
"     COMBINING PSYCHOTHERAPY AND PHARMACOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited study has found little sustained difference in efficacy between combined",
"    <span class=\"nowrap\">",
"     CBT/SSRI",
"    </span>",
"    treatment for PTSD and either intervention as monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    D-cycloserine has shown promise in preliminary studies in the augmentation of exposure therapy for several anxiety disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/37\">",
"     37",
"    </a>",
"    ]. Clinical trials of D-cycloserine for PTSD are currently underway. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=see_link&amp;anchor=H5614762#H5614762\">",
"     \"Pharmacotherapy for posttraumatic stress disorder\", section on 'Combining pharmacotherapy and psychotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19958403\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical interventions to prevent the development of PTSD have been tested in individuals who have experienced a traumatic event as well as individuals who have developed an acute stress disorder following a traumatic event. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24197?source=see_link&amp;anchor=H21033148#H21033148\">",
"     \"Treatment of acute stress disorder\", section on 'Cognitive-behavioral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4968728\">",
"    <span class=\"h2\">",
"     Cognitive behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intervention in people with acute stress disorder with trauma-focused cognitive behavioral therapy (CBT) has been found to reduce the likelihood of PTSD development [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/38\">",
"     38",
"    </a>",
"    ]. A meta-analysis of five randomized trials found that CBT reduced the proportion of patients meeting diagnostic criteria for PTSD at six months (relative risk = 0.56 [95% CI, 0.42 to 0.76]), with continued benefit seen at three years follow up. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24197?source=see_link\">",
"     \"Treatment of acute stress disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A more recent randomized trial found that CBT administered to individuals meeting PTSD symptom criteria an average of a month following exposure to a traumatic event was more effective than a waitlist control in reducing PTSD at five months following treatment initiation but no more effective at nine months. Two hundred and forty two patients were randomized to receive prolonged exposure (PE), cognitive therapy or a wait list control, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25481?source=see_link\">",
"     escitalopram",
"    </a>",
"    or pill placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/34\">",
"     34",
"    </a>",
"    ]. An equipoise-stratified randomization design allowed patients to refuse randomization to up to two treatment arms: 42.6 percent declined the",
"    <span class=\"nowrap\">",
"     escitalopram/placebo",
"    </span>",
"    arms, 5 percent declined wait list, 3.3 percent declined cognitive therapy, and 1.2 percent declined prolonged exposure. Compared to patients in the wait list group, patients receiving PE (57.1 versus 21.6 percent) or cognitive therapy (58.7 versus 20.0 percent) were less likely to have PTSD after five months, but no difference between groups was seen at nine months. No difference was seen in the rate of PTSD in patients who received escitalopram compared to pill placebo (61.9 versus 55.6 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19958352\">",
"    <span class=\"h2\">",
"     Psychological debriefing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite extensive use following disasters and other traumatic events, psychological debriefing has not been found to be effective in preventing PTSD among individuals experiencing a traumatic event [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Also known as \"critical incident stress debriefing\", the intervention involves recollecting, articulating, and reworking of the traumatic event, typically in a group format. Meta-analyses of numerous clinical trials found no evidence of effectiveness for either the initial, single-session intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/39\">",
"     39",
"    </a>",
"    ] or for subsequent, multiple-session versions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5032/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/45/8914?source=see_link\">",
"       \"Patient information: Post-traumatic stress disorder (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1118664290\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive therapy for PTSD aims to help patients correct erroneous cognitions. Behavioral therapy for PTSD seeks to decrease symptoms through exposure. CBT includes both cognitive and behavioral components, often along with other components such as education and coping skills training. (See",
"    <a class=\"local\" href=\"#H1118664211\">",
"     'Cognitive behavioral therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend treatment of PTSD with exposure therapy (eg, prolonged exposure), with a program that combines exposure therapy and cognitive therapy (eg, cognitive processing therapy), or with eye movement desensitization and reprocessing (EMDR) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Trials have found these types of psychotherapy to decrease PTSD symptoms compared to control conditions. (See",
"      <a class=\"local\" href=\"#H1118664160\">",
"       'Cognitive and behavioral therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Based on our clinical experience, we suggest use of one of these psychotherapies over medication for first-line treatment of PTSD (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Comparative trials are lacking between psychotherapy and medication for PTSD. (See",
"      <a class=\"local\" href=\"#H1118664160\">",
"       'Cognitive and behavioral therapies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1118664225\">",
"       'Eye movement desensitization and reprocessing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have not improved after eight or more sessions with a particular psychotherapy, a shift to another evidence based psychotherapy or pharmacotherapy should be considered. A selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) can also be used if cognitive and behavioral psychotherapies are not available or if medication treatment is preferred. (See",
"      <a class=\"local\" href=\"#H1118664160\">",
"       'Cognitive and behavioral therapies'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=see_link\">",
"       \"Pharmacotherapy for posttraumatic stress disorder\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Virtual reality exposure may be useful for the treatment of PTSD, however, randomized trials have not been published. The immersive experience it can provide may be particularly useful for highly avoidant patients who are hard to engage. (See",
"      <a class=\"local\" href=\"#H1118664197\">",
"       'Exposure therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Trauma-focused CBT for patients with acute stress disorder has been shown to be efficacious in reducing the likelihood of subsequent development of PTSD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24197?source=see_link&amp;anchor=H21033170#H21033170\">",
"       \"Treatment of acute stress disorder\", section on 'Efficacy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Institutes of Medicine. Treatment of Posttraumatic Stress Disorder: An Assessment of the Evidence, National Academies Press, Washington, DC 2008.",
"    </li>",
"    <li>",
"     National Institute for Clinical Excellence. Post Traumatic Stress Disorder: The management of PTSD in children and adults in primary and secondary care. The Royal College of Psychiatrists and British Psychological Society, 2005.",
"    </li>",
"    <li>",
"     Veterans Health Administration Department of defense (2004). VA/DOD Clinical Practice Guideline for the management of post traumatic stress. Version 1.0. Washington DC: Veterans Health Administration, Department of Defense.",
"    </li>",
"    <li>",
"     American Psychiatric Association. Practice guidelines for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Arlington, VA 2004.",
"    </li>",
"    <li>",
"     Cahill S, Rothbaum B, Resick P, Follette V. Cognitive-behavioral therapy for adults. In: Effective treatments for PTSD: Practice guidelines from the International Society for Traumatic Stress Studies, 2nd ed., Guilford Press, New York 2009. p.139.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/6\">",
"      Rothbaum BO, Foa EB, Riggs D, et al.. Prospective examination of post-traumatic stress disorder in rape victims. J Trauma Stress 1992; 5:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/7\">",
"      Rothbaum BO, Davis M. Applying learning principles to the treatment of post-trauma reactions. Ann N Y Acad Sci 2003; 1008:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/8\">",
"      Foa EB, Kozak MJ. Emotional processing of fear: exposure to corrective information. Psychol Bull 1986; 99:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/9\">",
"      Foa EB, Steketee G, Rothbaum BO. Behavioral/cognitive conceptualizations of post-traumatic stress disorder. Behav Ther 1989; 20:155.",
"     </a>",
"    </li>",
"    <li>",
"     Foa EB, Hembree E, Rothbaum BO. Prolonged Exposure Therapy for PTSD: Emotional Processing of Traumatic Experiences, Therapist Guide, Oxford University Press, New York 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/11\">",
"      Brom D, Kleber RJ, Defares PB. Brief psychotherapy for posttraumatic stress disorders. J Consult Clin Psychol 1989; 57:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/12\">",
"      Rothbaum BO, Hodges LF, Ready D, et al. Virtual reality exposure therapy for Vietnam veterans with posttraumatic stress disorder. J Clin Psychiatry 2001; 62:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/13\">",
"      Difede J, Cukor J, Jayasinghe N, et al. Virtual reality exposure therapy for the treatment of posttraumatic stress disorder following September 11, 2001. J Clin Psychiatry 2007; 68:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/14\">",
"      Gerardi M, Rothbaum BO, Ressler K, et al. Virtual reality exposure therapy using a virtual Iraq: case report. J Trauma Stress 2008; 21:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/15\">",
"      Beck JG, Palyo SA, Winer EH, et al. Virtual Reality Exposure Therapy for PTSD symptoms after a road accident: an uncontrolled case series. Behav Ther 2007; 38:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/16\">",
"      Schnurr PP, Friedman MJ, Engel CC, et al. Cognitive behavioral therapy for posttraumatic stress disorder in women: a randomized controlled trial. JAMA 2007; 297:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/17\">",
"      Difede J, Hoffman HG. Virtual reality exposure therapy for World Trade Center Post-traumatic Stress Disorder: a case report. Cyberpsychol Behav 2002; 5:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/18\">",
"      Difede J, Cukor J, Patt I, et al. The application of virtual reality to the treatment of PTSD following the WTC attack. Ann N Y Acad Sci 2006; 1071:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/19\">",
"      Parsons TD, Rizzo AA. Affective outcomes of virtual reality exposure therapy for anxiety and specific phobias: a meta-analysis. J Behav Ther Exp Psychiatry 2008; 39:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/20\">",
"      Bisson J, Andrew M. Psychological treatment of post-traumatic stress disorder (PTSD). Cochrane Database Syst Rev 2007; :CD003388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/21\">",
"      Tarrier N, Pilgrim H, Sommerfield C, et al. A randomized trial of cognitive therapy and imaginal exposure in the treatment of chronic posttraumatic stress disorder. J Consult Clin Psychol 1999; 67:13.",
"     </a>",
"    </li>",
"    <li>",
"     Resick, PA, Nishith, P, Astin, M. A controlled trial comparing cognitive processing therapy and prolonged exposure: preliminary findings. Paper presented at: Lake George Research Conference on Posttraumatic Stress Disorder, 1998; Lake George, NY.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/23\">",
"      Resick PA, Galovski TE, O'Brien Uhlmansiek M, et al. A randomized clinical trial to dismantle components of cognitive processing therapy for posttraumatic stress disorder in female victims of interpersonal violence. J Consult Clin Psychol 2008; 76:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/24\">",
"      van Emmerik AA, Kamphuis JH, Emmelkamp PM. Treating acute stress disorder and posttraumatic stress disorder with cognitive behavioral therapy or structured writing therapy: a randomized controlled trial. Psychother Psychosom 2008; 77:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/25\">",
"      Resick PA, Nishith P, Weaver TL, et al. A comparison of cognitive-processing therapy with prolonged exposure and a waiting condition for the treatment of chronic posttraumatic stress disorder in female rape victims. J Consult Clin Psychol 2002; 70:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/26\">",
"      Monson CM, Fredman SJ, Macdonald A, et al. Effect of cognitive-behavioral couple therapy for PTSD: a randomized controlled trial. JAMA 2012; 308:700.",
"     </a>",
"    </li>",
"    <li>",
"     Shapiro F. Eye Movement Desensitization and Reprocessing: Basic Protocols, Principles, Guilford, New York 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/28\">",
"      Foa EB, Rothbaum BO, Riggs DS, Murdock TB. Treatment of posttraumatic stress disorder in rape victims: a comparison between cognitive-behavioral procedures and counseling. J Consult Clin Psychol 1991; 59:715.",
"     </a>",
"    </li>",
"    <li>",
"     Foa EB, Keane TM, Friedman MJ, Cohen J. Effective treatments for PTSD: Practice guidelines from the International Society for Traumatic Stress Studies, 2nd ed., Guilford Press, New York 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/30\">",
"      Shapiro D. Behavioural and cognitive psychotherapy. Clin Psychol Rev 2003; 31:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/31\">",
"      Collins KA, Westra HA, Dozois DJ, Burns DD. Gaps in accessing treatment for anxiety and depression: challenges for the delivery of care. Clin Psychol Rev 2004; 24:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/32\">",
"      Demyttenaere K, Bruffaerts R, Posada-Villa J, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 2004; 291:2581.",
"     </a>",
"    </li>",
"    <li>",
"     Palmer S, Woolfe R. Integrative and eclectic counselling and psychotherapy, SAGE Publications, 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/34\">",
"      Shalev AY, Ankri Y, Israeli-Shalev Y, et al. Prevention of posttraumatic stress disorder by early treatment: results from the Jerusalem Trauma Outreach And Prevention study. Arch Gen Psychiatry 2012; 69:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/35\">",
"      Hetrick SE, Purcell R, Garner B, Parslow R. Combined pharmacotherapy and psychological therapies for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev 2010; :CD007316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/36\">",
"      Schneier FR, Neria Y, Pavlicova M, et al. Combined prolonged exposure therapy and paroxetine for PTSD related to the World Trade Center attack: a randomized controlled trial. Am J Psychiatry 2012; 169:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/37\">",
"      Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 2008; 63:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/38\">",
"      Korn&oslash;r H, Winje D, Ekeberg &Oslash;, et al. Early trauma-focused cognitive-behavioural therapy to prevent chronic post-traumatic stress disorder and related symptoms: a systematic review and meta-analysis. BMC Psychiatry 2008; 8:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/39\">",
"      Rose S, Bisson J, Churchill R, Wessely S. Psychological debriefing for preventing post traumatic stress disorder (PTSD). Cochrane Database Syst Rev 2002; :CD000560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5032/abstract/40\">",
"      Roberts NP, Kitchiner NJ, Kenardy J, Bisson J. Multiple session early psychological interventions for the prevention of post-traumatic stress disorder. Cochrane Database Syst Rev 2009; :CD006869.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14634 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-4327E6E395-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_58_5032=[""].join("\n");
var outline_f4_58_5032=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1118664290\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1118664153\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1118664160\">",
"      COGNITIVE AND BEHAVIORAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1118664169\">",
"      Theory",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1118664176\">",
"      - Basic science of conditioned fear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1118664183\">",
"      Cognitive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1118664190\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1118664197\">",
"      Exposure therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1118664204\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1118664211\">",
"      Cognitive behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1118664218\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H324030410\">",
"      Couples therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1118664225\">",
"      Eye movement desensitization and reprocessing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5497578\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1118664232\">",
"      Coping skills training",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1118664239\">",
"      PSYCHODYNAMIC PSYCHOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1118664246\">",
"      ECLECTIC PSYCHOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1118664276\">",
"      TREATMENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17273983\">",
"      COMPARING PSYCHOTHERAPY AND PSYCHOPHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15627796\">",
"      COMBINING PSYCHOTHERAPY AND PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19958403\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4968728\">",
"      Cognitive behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19958352\">",
"      Psychological debriefing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1118664290\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14634\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14634|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/33/30225\" title=\"picture 1\">",
"      Virtual Iraq Humvee scenario",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14634|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/39/6781\" title=\"table 1\">",
"      Prolonged exposure therapy session outline",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7080?source=related_link\">",
"      Acute stress disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/32/522?source=related_link\">",
"      Dissociative aspects of posttraumatic stress disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/45/8914?source=related_link\">",
"      Patient information: Post-traumatic stress disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=related_link\">",
"      Pharmacotherapy for posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=related_link\">",
"      Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24197?source=related_link\">",
"      Treatment of acute stress disorder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_58_5033="Substance use disorders: Principles for recognition and assessment in general medical care";
var content_f4_58_5033=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Substance use disorders: Principles for recognition and assessment in general medical care",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/58/5033/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/58/5033/contributors\">",
"     Michael F Weaver, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/58/5033/contributors\">",
"     Margaret A E Jarvis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/58/5033/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/58/5033/contributors\">",
"     Richard Saitz, MD, MPH, FACP, FASAM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/58/5033/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/58/5033/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/58/5033/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All clinicians will encounter patients with substance use disorders (SUDs). A study of a nationally representative sample found that eight percent of adults in the US had a SUD in the past 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/1\">",
"     1",
"    </a>",
"    ]. Up to 40 percent of hospital admissions are related to substance abuse and its sequelae, according to several cross-sectional studies of the prevalence of",
"    <span class=\"nowrap\">",
"     alcohol/drug",
"    </span>",
"    abuse and addiction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Addiction affects adolescents and the elderly, all races, and all socioeconomic strata. Despite the relatively high prevalence of SUDs, these disorders frequently go undetected in clinical care [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians should evaluate all new patients for alcohol and drug abuse; drug and alcohol use should also be considered when patients present with new symptoms, recent motor vehicle accidents or physical trauma, mood disorders, weight loss, or ongoing unexplained symptoms.",
"   </p>",
"   <p>",
"    Principles for recognition and assessment of SUDs in general medical care are discussed here. The epidemiology, clinical manifestations, course, diagnosis, and treatment for specific substances are discussed separately. Screening for alcohol and other drug use is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3784?source=see_link\">",
"     \"Opioid abuse and dependence: Overview and patient evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=see_link\">",
"     \"Treatment of opioid abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=see_link\">",
"     \"Opioid intoxication in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1079?source=see_link\">",
"     \"Cannabis use disorders: Epidemiology, comorbidity, and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21783?source=see_link\">",
"     \"Cannabis use disorders: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4554?source=see_link\">",
"     \"Cannabis use disorders: Treatment, prognosis, and long-term medical effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=see_link\">",
"     \"Cocaine abuse and dependence in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2409?source=see_link\">",
"     \"Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=see_link\">",
"     \"Pharmacotherapy for alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4361?source=see_link\">",
"     \"Ambulatory alcohol detoxification\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42265?source=see_link\">",
"     \"Brief intervention for unhealthy alcohol and other drug use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36535?source=see_link\">",
"     \"Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27160?source=see_link\">",
"     \"Prescription drug abuse and addiction: Prevention, identification, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1971288\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should be interviewed for a possible substance use disorder (SUD). Substance abuse is easy to recognize in the patient who has just been arrested for a motor vehicle violation or who presents with a request to discontinue using drugs. Many more substance abusers will only be identified if specifically asked about the problem.",
"   </p>",
"   <p>",
"    Patient denial is a significant barrier to identifying patients needing help for substance dependence. Denial may exist even when the patient is directly asked about use or confronted with behaviors suspicious for substance abuse. Obtaining history from family members and employers can be helpful, but must be done in compliance with legal regulations protecting patient privacy. In the United States (US), patient privacy regulations (HIPAA and 42CFR) require that the patient sign a release of information that includes the name of the patient and the person the clinician will be communicating with, the specific information to be released to that person, the reason for the release of information, and a time frame within which the release of information remains valid. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Definitions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several terms are used to distinguish different patterns of substance use. The following definitions are in general use:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use &mdash; Sporadic consumption of alcohol or drugs with no adverse consequences of that consumption.",
"     </li>",
"     <li>",
"      Abuse &mdash; Although the frequency of consumption of alcohol or drugs may vary, some adverse consequences of that use are experienced by the user.",
"     </li>",
"     <li>",
"      Physical dependence &mdash; A state of adaptation that is manifested by a substance class-specific withdrawal syndrome that can be produced by abrupt cessation or rapid dose reduction of a substance, or by administration of an antagonist [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Psychological dependence &mdash; A subjective sense of a need for a specific psychoactive substance, either for its positive effects or to avoid negative effects associated with its abstinence [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Addiction &mdash; A primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. Addiction is characterized by behaviors that include impaired control over substance use, compulsive use, continued use despite harm, and craving [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Substance use disorders &mdash; The disorders, substance abuse and substance dependence, are defined by DSM-IV-TR diagnostic criteria (",
"      <a class=\"graphic graphic_table graphicRef74334 \" href=\"UTD.htm?27/54/28523\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef50295 \" href=\"UTD.htm?11/26/11692\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1971547\">",
"    <span class=\"h2\">",
"     Special populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some groups of patients have particular risk factors or may require special approaches to recognizing and treating SUDs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adolescents should be advised about the potential dangers of substances, such as alcohol and tobacco, which are legal (though not for their age group), as well as illegal substances. It may be helpful, when interviewing an adolescent, to begin by asking whether illicit drugs are available at school, whether the patient has close friends who use drugs, and whether the patient has access to drugs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19000?source=see_link\">",
"       \"Guidelines for adolescent preventive services\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Substance abuse is more prevalent in patients who are depressed, anxious, or have any other psychiatric comorbidity (including personality disorders), and in those who smoke tobacco and who abuse alcohol. An epidemiologic study of a nationally representative sample in the US found that 15 percent of persons with a mental disorder had a co-occurring SUD in the prior 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/7\">",
"       7",
"      </a>",
"      ] compared to a rate of 8 percent in the general adult population [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/1\">",
"       1",
"      </a>",
"      ]. Fifty-one percent of patients with a mental disorder had a SUD at some point over their lifetime. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36521?source=see_link\">",
"       \"Dual diagnosis: Severe mental illness and substance use disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Elderly patients are at risk of developing dependence on sedative-hypnotics prescribed for insomnia or anxiety. Use of these medications is strongly associated with an increased risk of falls and injury [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22602?source=see_link&amp;anchor=H13#H13\">",
"       \"Falls in older persons: Risk factors and patient evaluation\", section on 'Medication use'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pregnant women may not admit substance use because they have guilt about its effect on their pregnancy, and fear legal consequences, including loss of custody of children [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Health care workers may be at increased risk for addiction, due to high-stress occupations and access to controlled substances. Rates of SUDs among physicians are 10 to 12 percent, roughly equivalent to the prevalence in the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/11\">",
"       11",
"      </a>",
"      ]. Anesthesiologists, emergency room physicians, and psychiatrists have higher rates of identified SUD [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/12\">",
"       12",
"      </a>",
"      ]. Professionals often have the resources to conceal the addiction for a long time, and so may have advanced disease by the time they seek treatment. Impaired performance due to substance use may have a significant impact on patient care [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5562?source=see_link\">",
"       \"Impaired healthcare provider\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Addiction to prescribed medications, including opioids, sedative-hypnotics, and stimulants, often goes unrecognized. Patients may be prescribed mood altering medications and pain medications from several clinicians concurrently. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27160?source=see_link\">",
"       \"Prescription drug abuse and addiction: Prevention, identification, and management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pharmaceutical medications are also obtained illicitly and subject to abuse and dependence. Abuse of opioid analgesics often manifests as patients presenting with pain complaints. While it is necessary to carefully treat pain, there is also a need to recognize that addiction may present this way, and requires appropriate screening and monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/14\">",
"       14",
"      </a>",
"      ]. Urine drug testing can be particularly helpful in this regard. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36535?source=see_link\">",
"       \"Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1971255\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Preventive Services Task Force (USPSTF) has recommended that all adults in primary care be screened to identify unhealthy alcohol use [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/15\">",
"     15",
"    </a>",
"    ]. Screening can also be done for drugs other than alcohol, and in settings other than primary care, though the evidence on health outcomes (for screening and associated treatment) is either limited or mixed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19000?source=see_link&amp;anchor=H4#H4\">",
"     \"Guidelines for adolescent preventive services\", section on 'Screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some circumstances, full assessment is more appropriate than screening. These include treatment settings in which the prevalence of substance use disorders is known to be very high (eg, mental health, criminal justice).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1971578\">",
"    <span class=\"h1\">",
"     PATIENT HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough general medical history should be taken. Issues of special relevance for the patient suspected of using drugs and suggestions for eliciting information, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In asking about specific substances, it is often best to first ask about socially accepted substances, such as nicotine and caffeine (coffee, soda, energy drinks). This will establish some level of comfort for the patient in addressing questions about use. Reports of caffeine intoxication have been rising due to availability of energy drinks with high caffeine content; caffeine can produce a substance dependence syndrome in some individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inquire next about alcohol use. Specifically inquire about beer, wine, and whiskey, noting that many patients may not consider beer to be \"alcohol,\" which they equate with hard liquor.",
"     </li>",
"     <li>",
"      Inquire about over-the-counter substances, including caffeine pills,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"       pseudoephedrine",
"      </a>",
"      products,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"       dextromethorphan",
"      </a>",
"      products, and herbal preparations.",
"     </li>",
"     <li>",
"      Inquire about misuse or abuse of prescription medications such as opioid analgesics, sedatives for insomnia or anxiety, and stimulants for attention deficit disorder or weight loss.",
"     </li>",
"     <li>",
"      Finally, ask about illicit drugs. By this time, the patient should have a sense that the practitioner is soliciting information in a non-judgmental fashion for the purpose of helping. Marijuana, which is considered less problematic by users, widely prevalent, and carries less social stigma, should be asked about first. Inquiries should then be made about cocaine and heroin use, as well as other illegal drugs such as methamphetamine, hallucinogens, and inhalants.",
"     </li>",
"     <li>",
"      With the patient's permission, family members should be interviewed for insights and corroboration.",
"     </li>",
"     <li>",
"      For each substance, ask patients about quantity used (ie, number of standard drinks, quantity of powder, unit of sale from a dealer). Terms used for drug units vary regionally, and it is helpful to be familiar with local drug slang, and ask the patient to explain an unfamiliar term. The amount of money spent on a",
"      <span class=\"nowrap\">",
"       daily/weekly/monthly",
"      </span>",
"      basis for drugs may also be used to quantitate drug usage.",
"     </li>",
"     <li>",
"      Ask about frequency of substance use, length of the most recent pattern of use, and time of last use. It may be helpful to ask the patient about where, when, and with whom drugs or alcohol are most often used.",
"     </li>",
"     <li>",
"      Determine the route of administration: oral, intranasal (eg, \"snorting\" or \"sniffing\"), subcutaneous injection (\"skin popping\"), or intravenous (\"shooting up\"). It is important to ask whether the patient has ever injected drugs in the past or shared needles.",
"     </li>",
"     <li>",
"      If a history of drug or alcohol abuse is disclosed, ask about participation in Alcoholics Anonymous (AA) or Narcotics Anonymous (NA), prior detoxification or addiction treatment, and abstinence periods. What has been helpful in the past and what has been tried? How long was the longest period of abstinence or maintenance treatment without using illicit drugs?",
"     </li>",
"     <li>",
"      Ask the patient to describe both the positive aspects of his or her substance use and its negative consequences (eg, What do you like about it? Has it had negative effects on your life?). Favorable perceptions of substance use may provide insight into underlying problems, such as psychiatric symptoms or difficulty with interpersonal or sexual functioning, that the patient sought to ameliorate through substance use.",
"      <br/>",
"      <br/>",
"      The list of potential negative consequences of substance use is long and varied. It includes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Elevated risks of specific physical illnesses, traumatic accidents, burns, fractures, and other physical injuries. (See",
"      <a class=\"local\" href=\"#H1972954\">",
"       'Social history'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H1971905\">",
"       'Physical findings'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Increased risks of psychiatric problems including higher rates of anxiety, depression, cognitive impairment, and suicidality. (See",
"      <a class=\"local\" href=\"#H1973744\">",
"       'Psychiatric findings'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Problems in relationships, at work, or with legal or financial issues (See",
"      <a class=\"local\" href=\"#H1972954\">",
"       'Social history'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H1973744\">",
"       'Psychiatric findings'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1971774\">",
"    <span class=\"h1\">",
"     FAMILY HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A family history of substance dependence should alert clinicians to an increased likelihood of substance dependence. Children of alcoholics have a three- to four-fold increased risk of developing alcoholism. Risk for opioid dependence is also genetically influenced [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/17\">",
"     17",
"    </a>",
"    ]. A family history of substance dependence is a risk factor for relapse in patients with a history of substance dependence; these patients may warrant more intensive monitoring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2409?source=see_link\">",
"     \"Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3784?source=see_link\">",
"     \"Opioid abuse and dependence: Overview and patient evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1972954\">",
"    <span class=\"h1\">",
"     SOCIAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough social history of persons with substance abuse or dependence can reveal many potential clues to a substance use disorder (SUD), including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Problems at school or at work",
"     </li>",
"     <li>",
"      Relational problems with spouses and children",
"     </li>",
"     <li>",
"      Involvement in violence",
"     </li>",
"     <li>",
"      Traumatic accidents",
"     </li>",
"     <li>",
"      Legal charges for public intoxication, altercations, possession, or driving under the influence",
"     </li>",
"     <li>",
"      High risk sexual behavior",
"     </li>",
"     <li>",
"      Financial problems",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Having a partner who is a substance abuser can increase the risk of an SUD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/10\">",
"     10",
"    </a>",
"    ]. This is particularly important in female patients who are often introduced to and supplied with drugs by a male partner who abuses them.",
"   </p>",
"   <p>",
"    In the substance-using patient, relationships are often affected first, as the user constricts social contacts due to substance use, or in order to be with other users. Work is usually affected later in the progression of addiction, as work provides income for continued use, and for some (ie, healthcare workers) may also provide access to drugs of abuse. Loss of a job, frequent job changes for no apparent reason, and unexplained financial problems are often consequences of substance abuse. Chronic problems or sudden unexplained changes in a patient's behavior in one or more of these areas should prompt assessment for an SUD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1971905\">",
"    <span class=\"h1\">",
"     PHYSICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common findings on physical exam of patients with substance use disorders (SUDs) are described below. These include signs and symptoms of infection, particularly patients administering drugs intravenously. Susceptibility to infection in substance dependence may relate to impaired host immunity, skin or nasal colonization with potentially pathogenic organisms, poor hygiene, contaminated drug paraphernalia, adulterated drugs, and contamination introduced during the preparation of the drug for injection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/18\">",
"     18",
"    </a>",
"    ]. There is also a high correlation between substance use and sexual risk-taking behaviors that also contributes to infectious disease in this population.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evidence of localized or systemic infections include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Palpation of the abdomen may reveal an enlarged or shrunken liver due to alcoholic hepatitis or infectious hepatitis transmitted by sharing contaminated paraphernalia. Up to 90 percent of illicit injection drug users are infected with hepatitis C virus (HCV) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/19\">",
"       19",
"      </a>",
"      ]. Even among patients in treatment for addiction, HCV seropositivity is high, as evidenced by rates of 70 percent among patients in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      maintenance clinics [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link\">",
"       \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=see_link\">",
"       \"Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Physical examination may reveal clues to possible HIV infection, such as oral thrush [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/21\">",
"       21",
"      </a>",
"      ] or posterior cervical lymphadenopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43129?source=see_link\">",
"       \"Acute and early HIV infection: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bacterial infections in people who inject drugs may lead to skin or soft tissue abscesses, often involving methicillin-resistant S. aureus (MRSA). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43831?source=see_link\">",
"       \"Skin abscesses, furuncles, and carbuncles\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infective endocarditis is estimated to occur at a rate of 1.5 to 3.3 cases per 1000 injection drug-use years [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/22\">",
"       22",
"      </a>",
"      ], and rates are higher for those with concomitant HIV infection. Physical findings of infective endocarditis include a new heart murmur, splenomegaly, and petechiae of conjunctiva, oral mucosa, and arms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40215?source=see_link\">",
"       \"Infective endocarditis in injection drug users\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug users also have an increased risk of community-acquired pneumonia, and pulmonary tuberculosis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/18\">",
"       18",
"      </a>",
"      ]. Physical findings of pneumonia include a productive cough, hemoptysis (especially with pulmonary tuberculosis), dyspnea, and consolidation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      egophony changes to breath sounds heard with a stethoscope. Illicit drug use presents special challenges for tuberculosis management, including potential interactions of medications used to treat tuberculosis with underlying liver disease and with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      , and the need for direct observation to assure compliance with medication [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"       \"Diagnostic approach to community-acquired pneumonia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=see_link\">",
"       \"Clinical manifestations and evaluation of pulmonary tuberculosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Physical findings of sexually transmitted diseases (genital warts, HIV, syphilitic chancres, genital ulcers) should raise consideration of the possibility of drug abuse, as should reports or findings of unwanted pregnancies [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/24\">",
"       24",
"      </a>",
"      ]. Vaginal candidiasis is more prevalent among women who inject drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/21\">",
"       21",
"      </a>",
"      ]. A speculum exam may reveal vaginitis or cervicitis, and patients may have an abnormal Pap smear. As an example, one study found Pap smear abnormalities in 24 percent of pregnant women in an addiction treatment program [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link\">",
"       \"Screening for sexually transmitted infections\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Smoking or snorting cocaine and other drugs can cause respiratory problems (pneumomediastinum and decreased alveolar diffusion capacity), atrophy of the nasal mucosa, and perforation of the nasal septum [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34649?source=see_link\">",
"       \"Pulmonary complications of cocaine abuse\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Needle marks from recent injections may be present on the skin in IV drug users, or \"tracks\" may be present over veins from repeated injections. Injection is not always confined to the obvious sites. Many users will attempt to hide their problem by injecting in the axilla, under the tongue, under the breast, in the legs, and into the dorsal vein of the penis.",
"     </li>",
"     <li>",
"      Substance use and dependence may be an underlying cause of specific physical illnesses, traumatic accidents, burns, fractures, and other physical injuries",
"     </li>",
"     <li>",
"      Unexplained medical problems should prompt assessment for an SUD. An example is a sudden, unexplained exacerbation of previously well controlled diabetes mellitus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10617?source=see_link&amp;anchor=H10#H10\">",
"       \"Primary care management of medically unexplained symptoms\", section on 'Tapering and discontinuing addicting medications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Weight loss and sleep disturbance may be seen in patients with an SUD.",
"     </li>",
"     <li>",
"      There is mounting evidence that substance use is the leading cause of impotence in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25258?source=see_link\">",
"       \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42904?source=see_link\">",
"       \"The sexual history and approach to the patient with sexual dysfunction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=see_link\">",
"       \"Overview of male sexual dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Signs and symptoms of acute intoxication or acute withdrawal include bizarre behavior or behavior that is atypical for the patient, changes in arousal (agitation or sedation), abnormal pupillary size (dilation or constriction), tachycardia, conjunctival injection, sweating, watery eyes, runny nose, slurred speech, yawning, and unsteady gait. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=see_link\">",
"       \"Opioid intoxication in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21783?source=see_link\">",
"       \"Cannabis use disorders: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/34/44584?source=see_link\">",
"       \"Intoxication from LSD and other common hallucinogens\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=see_link\">",
"       \"Cocaine abuse and dependence in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/29/474?source=see_link\">",
"       \"Methamphetamine intoxication\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21560?source=see_link\">",
"       \"MDMA (ecstasy) intoxication\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1973744\">",
"    <span class=\"h1\">",
"     PSYCHIATRIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SUDs may present with depression (with or without suicidality), anxiety, agitation, or psychosis. (See",
"    <a class=\"local\" href=\"#H1971578\">",
"     'Patient history'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Substance users may exhibit symptoms of depression, including lack of energy, loss of interest in eating, and weight loss. Suicidal thinking and intent are seen in some addicts who feel hopeless and helpless. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"       \"Clinical manifestations and diagnosis of depression\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10377?source=see_link\">",
"       \"Suicidal ideation and behavior in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anxiety, agitation, sleep disturbance, and behavioral changes may be a sign of withdrawal from alcohol or",
"      <span class=\"nowrap\">",
"       sedative/hypnotics.",
"      </span>",
"      These signs and symptoms can occur in hospitalized patients with dependence who stop their use on admission; disruptive behavior may be a presenting sign [",
"      <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2409?source=see_link\">",
"       \"Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=see_link\">",
"       \"Benzodiazepine poisoning and withdrawal\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"       \"Management of moderate and severe alcohol withdrawal syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Psychosis may result from ingestion of prescribed stimulants, alcohol, cocaine, phencyclidine and other hallucinogens, or methamphetamines, or from withdrawal of alcohol or",
"      <span class=\"nowrap\">",
"       sedative/hypnotic",
"      </span>",
"      drugs such as barbiturates or benzodiazepines. In most instances the presence of offending substances is detectable; however, cases of persistent psychosis for days or weeks after a drug is cleared from the body have been described, especially with hallucinogens and amphetamines [",
"      <a class=\"external\" href=\"file://www.uptodate.com/contents/overview-of-psychosis/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=see_link\">",
"       \"Overview of psychosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several laboratory findings may suggest the presence of substance abuse. The mean corpuscular volume is elevated with long-term alcohol use. Liver enzymes can be elevated with alcohol use and infectious hepatitis acquired from sharing needles. Positive serology for hepatitis B or C can suggest drug abuse. Data from the CDC show that over 60 percent of newly acquired hepatitis C virus infections occur in individuals who have injected illegal drugs during the six months prior to disease onset. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology and transmission of hepatitis C virus infection\", section on 'Illicit drug use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Drug testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for drugs of abuse can be performed on multiple types of samples including urine, blood, breath, hair, saliva, and sweat. Urine testing is most widely used because it is noninvasive, simple to obtain, and yields a detectable concentration of most drugs; however, it does not measure impairment. Blood levels of drugs can provide more information about level of impairment, but must be obtained invasively and drug metabolism may shorten the time in which a drug can be detected in the bloodstream, compared to urine sampling. The best evidence for long-term drug use is the combination of a good history and a urine toxicology screen.",
"   </p>",
"   <p>",
"    A positive urine toxicology screen is an indication of recent drug use (past few days) but may not provide evidence of earlier use (",
"    <a class=\"graphic graphic_table graphicRef58181 \" href=\"UTD.htm?24/57/25499\">",
"     table 3",
"    </a>",
"    ). Screening tests for single or multiple drugs of abuse are commercially available and can test for virtually any combination. The drugs most commonly screened are opioids, alcohol, cocaine, marijuana, phencyclidine, and amphetamines. Other specific drugs can be tested and detected if requested.",
"   </p>",
"   <p>",
"    Screening tests are commonly based on immunoassay techniques, which allow for rapid and inexpensive testing. However, false positive tests can occur, with potentially profound medical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    social consequences. Positive screening tests should be confirmed by the more time consuming and costly techniques of mass spectroscopy and gas chromatography [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Validity and reliability of urine drug test results may be compromised by tampering with the sample. Substitution with another sample can be reduced by directly observing sample collection and following procedures for chain of custody. Samples may be adulterated by dilution or other available additives (many of which can be bought over the Internet) to interfere with the screening assay. In addition, ingesting large quantities of liquids, taking diuretics or adding water or household bleach to a urine sample may mask illicit drug use. False positive drug screens may be associated with use of Vicks Inhaler (amphetamine testing), NSAIDs (barbiturates and cannabinoids), or fluoroquinolones (opiates) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Requirements for notification or permission to obtain specimens for toxicology testing vary by jurisdiction. Patients should be asked for permission to perform testing. Testing for illegal drugs without consent, in the absence of medical indications, may be considered discriminatory, a violation of the patient's civil rights, or may constitute unlawful search and seizure. Informed consent helps to foster a positive therapeutic relationship between patients and caregivers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/58/5033/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/21/7506?source=see_link\">",
"       \"Patient information: Prescription drug abuse (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite a relatively high prevalence of substance use disorders (SUDs) (approximately eight percent of the general adult US population and up to 40 percent of inpatients in the US) SUDs frequently go undetected or unaddressed in clinical care. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All new patients should be assessed for substance abuse and dependence. The patient&rsquo;s history of use should be elicited in a non-judgmental fashion. Patients should be asked about individual substances and their quantity, frequency, duration, route of administration, consequences, and prior treatment. With the patient's permission, family members should be interviewed for insights and corroboration. (See",
"      <a class=\"local\" href=\"#H1971578\">",
"       'Patient history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A family history of alcohol or opioid dependence should alert clinicians to a patient&rsquo;s increased risk of dependence. (See",
"      <a class=\"local\" href=\"#H1971774\">",
"       'Family history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Substance use should be suspected in the patient with behavioral changes affecting family or work, family or partner history of substance abuse, or frequent legal entanglements. Substance use can cause sexual impairment or high risk sexual behavior. (See",
"      <a class=\"local\" href=\"#H1972954\">",
"       'Social history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical examination in substance users may reveal evidence of needle or track marks, nasal septal perforation, liver damage, HIV-related infections, genital infections, and other illnesses. (See",
"      <a class=\"local\" href=\"#H1971905\">",
"       'Physical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Substance use or withdrawal can cause or contribute to depression, anxiety, agitation, psychosis, cognitive impairment, and suicidality. (See",
"      <a class=\"local\" href=\"#H1973744\">",
"       'Psychiatric findings'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1971578\">",
"       'Patient history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drug testing can be performed on multiple body tissues and secretions, but is most commonly done on blood or urine samples. Urine testing is most readily accomplished, but patients may try to hide the presence of illicit substances with sample substitution, dilution, or masking agents. Polysubstance abuse is common. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Drug testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/1\">",
"      Narrow WE, Rae DS, Robins LN, Regier DA. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates. Arch Gen Psychiatry 2002; 59:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/2\">",
"      Santora PB, Hutton HE. Longitudinal trends in hospital admissions with co-occurring alcohol/drug diagnoses, 1994-2002. J Subst Abuse Treat 2008; 35:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/3\">",
"      Mordal J, Bramness JG, Holm B, M&oslash;rland J. Drugs of abuse among acute psychiatric and medical admissions: laboratory based identification of prevalence and drug influence. Gen Hosp Psychiatry 2008; 30:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/4\">",
"      Miller NS, Giannini AJ, Gold MS, Philomena JA. Drug testing: medical, legal, and ethical issues. J Subst Abuse Treat 1990; 7:239.",
"     </a>",
"    </li>",
"    <li>",
"     American Society of Addiction Medicine: ASAM Addiction Terminology. In: Graham, AW, Shultz, TK (Eds), Principles of Addiction Medicine, 3rd Ed, American Society of Addiction Medicine, Inc, Chevy Chase, MD 2003. p.1601.",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, American Psychiatric Association, Washington, DC 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/7\">",
"      Kessler RC, Nelson CB, McGonagle KA, et al. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry 1996; 66:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/8\">",
"      Hartikainen S, L&ouml;nnroos E, Louhivuori K. Medication as a risk factor for falls: critical systematic review. J Gerontol A Biol Sci Med Sci 2007; 62:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/9\">",
"      Finkle WD, Der JS, Greenland S, et al. Risk of fractures requiring hospitalization after an initial prescription for zolpidem, alprazolam, lorazepam, or diazepam in older adults. J Am Geriatr Soc 2011; 59:1883.",
"     </a>",
"    </li>",
"    <li>",
"     Weaver, MF. Perinatal addiction. In: Principles of addiction medicine, 3rd ed, Graham, AW, Shultz, TK (Eds), American Society of Addiction Medicine, Inc., Chevy Chase, MD 2003. p.1231.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/11\">",
"      DuPont RL, McLellan AT, Carr G, et al. How are addicted physicians treated? A national survey of Physician Health Programs. J Subst Abuse Treat 2009; 37:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/12\">",
"      Berge KH, Seppala MD, Schipper AM. Chemical dependency and the physician. Mayo Clin Proc 2009; 84:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/13\">",
"      Baldisseri MR. Impaired healthcare professional. Crit Care Med 2007; 35:S106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/14\">",
"      Weaver, MF, Schnoll, SH. Risk assessment for opioid misuse in chronic pain treatment. Adv Pain Manage 2008; 2:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/15\">",
"      U.S. Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: recommendation statement. Ann Intern Med 2004; 140:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/16\">",
"      Reissig CJ, Strain EC, Griffiths RR. Caffeinated energy drinks--a growing problem. Drug Alcohol Depend 2009; 99:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/17\">",
"      Gelernter J, Panhuysen C, Wilcox M, et al. Genomewide linkage scan for opioid dependence and related traits. Am J Hum Genet 2006; 78:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/18\">",
"      Gordon RJ, Lowy FD. Bacterial infections in drug users. N Engl J Med 2005; 353:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/19\">",
"      Gish RG, Afdhal NH, Dieterich DT, Reddy KR. Management of hepatitis C virus in special populations: patient and treatment considerations. Clin Gastroenterol Hepatol 2005; 3:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/20\">",
"      Weaver MF, Cropsey KL, Fox SA. HCV prevalence in methadone maintenance: self-report versus serum test. Am J Health Behav 2005; 29:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/21\">",
"      Schuman P, Sobel JD, Ohmit SE, et al. Mucosal candidal colonization and candidiasis in women with or at risk for human immunodeficiency virus infection. HIV Epidemiology Research Study (HERS) Group. Clin Infect Dis 1998; 27:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/22\">",
"      Wilson LE, Thomas DL, Astemborski J, et al. Prospective study of infective endocarditis among injection drug users. J Infect Dis 2002; 185:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/23\">",
"      Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and illicit drug use: review and update. Clin Infect Dis 2009; 48:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/24\">",
"      Minkoff HL, McCalla S, Delke I, et al. The relationship of cocaine use to syphilis and human immunodeficiency virus infections among inner city parturient women. Am J Obstet Gynecol 1990; 163:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/25\">",
"      Glassroth J, Adams GD, Schnoll S. The impact of substance abuse on the respiratory system. Chest 1987; 91:596.",
"     </a>",
"    </li>",
"    <li>",
"     Masters, WH, Johnson, VE. Human Sexual Inadequacy, Little Brown &amp; Co Inc., Boston, MA 1970.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/27\">",
"      Williams G, Daly M, Proude EM, et al. The influence of alcohol and tobacco use in orthopaedic inpatients on complications of surgery. Drug Alcohol Rev 2008; 27:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/28\">",
"      Moeller KE, Lee KC, Kissack JC. Urine drug screening: practical guide for clinicians. Mayo Clin Proc 2008; 83:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/58/5033/abstract/29\">",
"      Vincent EC, Zebelman A, Goodwin C, Stephens MM. Clinical inquiries. What common substances can cause false positives on urine screens for drugs of abuse? J Fam Pract 2006; 55:893.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7807 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-8F853297CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_58_5033=[""].join("\n");
var outline_f4_58_5033=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1971288\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Definitions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1971547\">",
"      Special populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1971255\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1971578\">",
"      PATIENT HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1971774\">",
"      FAMILY HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1972954\">",
"      SOCIAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1971905\">",
"      PHYSICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1973744\">",
"      PSYCHIATRIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Drug testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/7807\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/7807|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/54/28523\" title=\"table 1\">",
"      DSM-IV-TR criteria for substance abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/26/11692\" title=\"table 2\">",
"      Criteria substance dependence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/57/25499\" title=\"table 3\">",
"      Urine test drugs of abuse",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43129?source=related_link\">",
"      Acute and early HIV infection: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2409?source=related_link\">",
"      Alcohol abuse and dependence: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4361?source=related_link\">",
"      Ambulatory alcohol detoxification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=related_link\">",
"      Benzodiazepine poisoning and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42265?source=related_link\">",
"      Brief intervention for unhealthy alcohol and other drug use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21783?source=related_link\">",
"      Cannabis use disorders: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1079?source=related_link\">",
"      Cannabis use disorders: Epidemiology, comorbidity, and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4554?source=related_link\">",
"      Cannabis use disorders: Treatment, prognosis, and long-term medical effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=related_link\">",
"      Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=related_link\">",
"      Clinical manifestations and evaluation of pulmonary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=related_link\">",
"      Cocaine abuse and dependence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36521?source=related_link\">",
"      Dual diagnosis: Severe mental illness and substance use disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=related_link\">",
"      Epidemiology and transmission of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22602?source=related_link\">",
"      Falls in older persons: Risk factors and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19000?source=related_link\">",
"      Guidelines for adolescent preventive services",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/27/5562?source=related_link\">",
"      Impaired healthcare provider",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40215?source=related_link\">",
"      Infective endocarditis in injection drug users",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/34/44584?source=related_link\">",
"      Intoxication from LSD and other common hallucinogens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21560?source=related_link\">",
"      MDMA (ecstasy) intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=related_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/474?source=related_link\">",
"      Methamphetamine intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3784?source=related_link\">",
"      Opioid abuse and dependence: Overview and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=related_link\">",
"      Opioid intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=related_link\">",
"      Overview of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=related_link\">",
"      Overview of psychosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/21/7506?source=related_link\">",
"      Patient information: Prescription drug abuse (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=related_link\">",
"      Pharmacotherapy for alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36535?source=related_link\">",
"      Prescription drug abuse and addiction: Clinical features, epidemiology, and contributing factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27160?source=related_link\">",
"      Prescription drug abuse and addiction: Prevention, identification, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10617?source=related_link\">",
"      Primary care management of medically unexplained symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=related_link\">",
"      Psychosocial treatment of alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34649?source=related_link\">",
"      Pulmonary complications of cocaine abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=related_link\">",
"      Screening for unhealthy use of alcohol and other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25258?source=related_link\">",
"      Sexual dysfunction in women: Epidemiology, risk factors, and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43831?source=related_link\">",
"      Skin abscesses, furuncles, and carbuncles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10377?source=related_link\">",
"      Suicidal ideation and behavior in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42904?source=related_link\">",
"      The sexual history and approach to the patient with sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=related_link\">",
"      Treatment of opioid abuse and dependence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_58_5034="Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information";
var content_f4_58_5034=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trimethoprim-sulfamethoxazole (co-trimoxazole): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/2/23589?source=see_link\">",
"    see \"Trimethoprim-sulfamethoxazole (co-trimoxazole): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"    see \"Trimethoprim-sulfamethoxazole (co-trimoxazole): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F154885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bactrim&trade;;",
"     </li>",
"     <li>",
"      Bactrim&trade; DS;",
"     </li>",
"     <li>",
"      Septra&reg; DS",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F154886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Sulfatrim&reg;;",
"     </li>",
"     <li>",
"      Apo-Sulfatrim&reg; DS;",
"     </li>",
"     <li>",
"      Apo-Sulfatrim&reg; Pediatric;",
"     </li>",
"     <li>",
"      Novo-Trimel;",
"     </li>",
"     <li>",
"      Novo-Trimel D.S.;",
"     </li>",
"     <li>",
"      Nu-Cotrimox;",
"     </li>",
"     <li>",
"      Septra&reg; Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F154907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Miscellaneous;",
"     </li>",
"     <li>",
"      Antibiotic, Sulfonamide Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F154889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage recommendations are based on the trimethoprim component. double-strength tablets are equivalent to sulfamethoxazole 800 mg and trimethoprim 160 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      General dosing guidelines:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 1-2 double-strength tablets (sulfamethoxazole 800 mg; trimethoprim 160 mg) every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 8-20 mg TMP/kg/day divided every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic bronchitis (acute):",
"     </b>",
"     Oral: One double-strength tablet every 12 hours for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cyclosporiasis (unlabeled use):",
"     </b>",
"     Oral, I.V.: 160 mg TMP twice daily for 7-10 days.",
"     <b>",
"      Note:",
"     </b>",
"     AIDS patients: Oral: One double-strength tablet 2-4 times/day for 10 days, then 1 double-strength tablet 3 times/week for 10 weeks (Pape, 1994; Verdier, 2000).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Granuloma inguinale (donovanosis) (unlabeled use):",
"     </b>",
"     Oral: One double-strength tablet every 12 hours for at least 3 weeks and until lesions have healed (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Isosporiasis (",
"      <i>",
"       Isospora belli",
"      </i>",
"      infection) in HIV-positive patients (unlabeled use; CDC, 2009):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment: Oral, I.V.: 160 mg TMP 4 times/day for 10 days",
"     <b>",
"      or",
"     </b>",
"     160 mg TMP 2 times/day for 7-10 days. May increase dose and/or duration up to 3-4 weeks if symptoms worsen or persist",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Secondary prophylaxis (in patients with CD4+ count &lt;200 /microL): Oral: 160 mg TMP 3 times/week (preferred)",
"     <b>",
"      or",
"     </b>",
"     alternatively, 160 mg TMP daily",
"     <b>",
"      or",
"     </b>",
"     320 mg TMP 3 times/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Meningitis (bacterial):",
"     </b>",
"     I.V.: 10-20 mg TMP/kg/day in divided doses every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Nocardia",
"      </i>",
"     </b>",
"     (unlabeled use): Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cutaneous infections: 5-10 mg TMP/kg/day in 2-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe infections (pulmonary/cerebral): 15 mg TMP/kg/day in 2-4 divided doses for 3-4 weeks, then 10 mg TMP/kg/day in 2-4 divided doses. Treatment duration is controversial; an average of 7 months has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Therapy for severe infection may be initiated I.V. and converted to oral therapy (frequently converted to approximate dosages of oral solid dosage forms: 2 DS tablets every 8-12 hours). Although not widely available, sulfonamide levels should be considered in patients with questionable absorption, at risk for dose-related toxicity, or those with poor therapeutic response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteomyelitis due to MRSA (unlabeled use):",
"     </b>",
"     Oral, I.V.: 3.5-4 mg TMP/kg/dose every 8-12 hours for a minimum of 8 weeks with rifampin 600 mg once daily (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Pneumocystis jirovecii",
"      </i>",
"      pneumonia (PCP):",
"     </b>",
"     Oral: Manufacturer&rsquo;s labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prophylaxis: 160 mg TMP daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment: 15-20 mg TMP/kg/day divided every 6 hours for 14-21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Pneumocystis jirovecii",
"      </i>",
"      pneumonia (PCP) prophylaxis and treatment in HIV-positive patients (CDC, 2009): Note:",
"     </b>",
"     Sulfamethoxazole and trimethoprim is the preferred regimen for this indication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prophylaxis: Oral: 80-160 mg TMP daily",
"     <b>",
"      or",
"     </b>",
"     alternatively, 160 mg TMP 3 times/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild-to-moderate: Oral: 15-20 mg TMP/kg/day in 3 divided doses for 21 days",
"     <b>",
"      or",
"     </b>",
"     alternatively, 320 mg TMP 3 times/day for 21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Moderate-to-severe: Oral, I.V.: 15-20 mg TMP/kg/day in 3-4 divided doses for 21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prosthetic joint infection (unlabeled use):",
"     </b>",
"     Oral phase treatment (after completion of pathogen-specific I.V. therapy) following debridement and prosthesis retention or 1-stage exchange:",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;margin-right:2em;text-align:justify;\">",
"     Total ankle, elbow, hip, or shoulder arthroplasty: 160 mg TMP 2 times daily for 3 months.",
"     <b>",
"      Note:",
"     </b>",
"     Must be used in combination with rifampin (Cordero-Ampuero, 2007; Osmon, 2013).",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;margin-right:2em;text-align:justify;\">",
"     Total knee arthroplasty: Adults: 160 mg TMP 2 times daily for 6 months.",
"     <b>",
"      Note:",
"     </b>",
"     Must be used in combination with rifampin (Cordero-Ampuero, 2007; Osmon, 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sepsis:",
"     </b>",
"     I.V.: 20 TMP/kg/day divided every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Septic arthritis due to MRSA (unlabeled use):",
"     </b>",
"     Oral, I.V.: 3.5-4 mg TMP/kg/dose every 8-12 hours for 3-4 weeks (some experts combine with rifampin) (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shigellosis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: One double-strength tablet every 12 hours for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 8-10 mg TMP/kg/day in divided doses every 6, 8, or 12 hours for up to 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Skin/soft tissue infection due to community-acquired MRSA (unlabeled use):",
"     </b>",
"     Oral: 1-2 double-strength tablets every 12 hours for 5-10 days (Liu,  2011);",
"     <b>",
"      Note:",
"     </b>",
"     If beta-hemolytic",
"     <i>",
"      Streptococcus",
"     </i>",
"     spp are also suspected, a beta-lactam antibiotic should be added to the regimen (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Stenotrophomonas maltophilia",
"      </i>",
"     </b>",
"     <b>",
"      (ventilator-associated pneumonia):",
"     </b>",
"     I.V.: Most clinicians have utilized 12-15 mg TMP/kg/day for the treatment of VAP caused by",
"     <i>",
"      Stenotrophomonas maltophilia",
"     </i>",
"     .  Higher doses (up to 20 mg TMP/kg/day) have been mentioned for treatment of severe infection in patients with normal renal function (Looney, 2009; Vartivarian, 1989; Wood, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Toxoplasma gondii",
"      </i>",
"      encephalitis (unlabeled use; CDC, 2009):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Primary prophylaxis: Oral: 160 mg TMP daily (preferred)",
"     <b>",
"      or",
"     </b>",
"     160 mg TMP 3 times/week",
"     <b>",
"      or",
"     </b>",
"     80 mg TMP daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment (alternative to sulfadiazine, pyrimethamine and leucovorin calcium): Oral, I.V.: 5 mg/kg TMP twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Travelers' diarrhea:",
"     </b>",
"     Oral: One double-strength tablet every 12 hours for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Urinary tract infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: One double-strength tablet every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Duration of therapy: Uncomplicated: 3-5 days; Complicated: 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Pyelonephritis: 14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Prostatitis: Acute: 2 weeks; Chronic: 2-3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 8-10 mg TMP/kg/day in divided doses every 6, 8, or 12 hours for up to 14 days with severe infections",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F154900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"      see \"Trimethoprim-sulfamethoxazole (co-trimoxazole): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations are based on the trimethoprim component.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      General dosing guidelines:",
"     </b>",
"     Children &gt;2 months: Manufacturer&rsquo;s labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Mild-to-moderate infections:",
"     </b>",
"     Oral: 8 mg TMP/kg/day in divided doses every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Serious infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 15-20 mg TMP/kg/day in divided doses every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 8-12 mg TMP/kg/day in divided doses every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Acute otitis media:",
"     </b>",
"     Oral: 8 mg TMP/kg/day in divided doses every 12 hours for 10 days.",
"     <b>",
"      Note:",
"     </b>",
"     Recommended by the American Academy of Pediatrics as an alternative agent in penicillin allergic patients at a dose of 6-10mg TMP/kg/day (AOM guidelines, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Cyclosporiasis (unlabeled use):",
"     </b>",
"     Oral, I.V.: 5 mg TMP/kg twice daily for 7-10 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Pneumocystis:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: Oral, I.V.: 15-20 mg TMP/kg/day in divided doses every 6-8 hours for 21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis: Oral: 150 mg TMP/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in divided doses every 12 hours and administered for 3 days/week on consecutive or alternate days; an alternative dosing regimen allows for same dose to be administered in 2 divided doses daily (maximum: trimethoprim 320 mg and sulfamethoxazole 1600 mg daily) (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Shigellosis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 8 mg TMP/kg/day in divided doses every 12 hours for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 8-10 mg TMP/kg/day in divided doses every 6, 8, or 12 hours for up to 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Skin/soft tissue infection due to community-acquired MRSA (unlabeled use):",
"     </b>",
"     Oral: 4-6 mg TMP/kg/dose every 12 hours for 5-10 days (Liu, 2011);",
"     <b>",
"      Note:",
"     </b>",
"     If beta-hemolytic",
"     <i>",
"      Streptococcus",
"     </i>",
"     spp are also suspected, a beta-lactam antibiotic should be added to the regimen (Liu, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Toxoplasmosis primary prophylaxis in HIV-exposed/infected patients (unlabeled use; CDC, 2009):",
"     </b>",
"     Oral: 150 mg TMP/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 2 divided doses (preferred) or 150 mg TMP/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in a single dose 3 times/week on consecutive days or 150 mg TMP/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 2 divided doses 3 times/week on alternate days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Urinary tract infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oral: 8 mg TMP/kg/day in divided doses every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     I.V.: 8-10 mg TMP/kg/day in divided doses every 6, 8, or 12 hours for up to 14 days with serious infections",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis: Oral: 2 mg TMP/kg/dose daily or 5 mg TMP/kg/dose twice weekly",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F154890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F154891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Manufacturer&rsquo;s recommendation: Children and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute: No dosage adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-30 mL/minute: Administer 50% of recommended dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute: Use is not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Alternate recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-30 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: Administer full daily dose (divided every 12 hours) for 24-48 hours, then decrease daily dose by 50% and administer every 24 hours (",
"     <b>",
"      Note:",
"     </b>",
"     For serious infections including",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia (PCP), full daily dose is given in divided doses every 6-8 hours for 2 days, followed by reduction to 50% daily dose divided every 12 hours) (Nahata, 1995).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PCP prophylaxis: One-half single-strength tablet (40 mg trimethoprim) daily",
"     <b>",
"      or",
"     </b>",
"     1 single-strength tablet (80 mg trimethoprim) daily or 3 times weekly (Masur, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: Administer full daily dose every 48 hours (Nahata, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PCP prophylaxis: One-half single-strength tablet (40 mg trimethoprim) daily",
"     <b>",
"      or",
"     </b>",
"     1 single-strength tablet (80 mg trimethoprim) 3 times weekly (Masur, 2002). While the guidelines do acknowledge the alternative of giving 1 single-strength tablet daily, this may be inadvisable in the uremic/ESRD patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GFR &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Children: Use is not recommended, but if required, administer 5-10 mg trimethoprim/kg every 24 hours (Aronoff, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intermittent Hemodialysis (IHD) (administer after hemodialysis on dialysis days):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Use is not recommended, but if required, administer 5-10 mg trimethoprim/kg every 24 hours (Aronoff, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 2.5-10 mg/kg trimethoprim every 24 hours or 5-20 mg/kg trimethoprim 3 times weekly after IHD.",
"     <b>",
"      Note:",
"     </b>",
"     Dosing is highly dependent upon indication for use (eg, treatment of cystitis versus treatment of PCP pneumonia (Heinz, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PCP prophylaxis: One single-strength tablet (80 mg trimethoprim) after each dialysis session (Masur, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of 3 times/week, complete IHD sessions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis (PD):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Use Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute dosing recommendations. Not significantly removed by PD; supplemental dosing is not required (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GFR &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Children: Use is not recommended, but if required 5-10 mg TMP/kg every 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Exit-site and tunnel infections: Oral: One single-strength tablet daily (Li, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intraperitoneal: Loading dose: TMP-SMX 320/1600 mg/L; Maintenance: TMP-SMX 80/400 mg/L (Aronoff, 2007; Warady, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peritonitis: Oral: One double-strength tablet twice daily (Li, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVH/CVVHD/CVVHDF: 2.5-7.5 mg/kg of TMP every 12 hours.",
"     <b>",
"      Note:",
"     </b>",
"     Dosing regimen dependent on clinical indication. Critically-ill patients with",
"     <i>",
"      P. jirovecii",
"     </i>",
"     pneumonia receiving CVVHDF may require up to 10 mg/kg every 12 hours (Heintz, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F154857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"     <b>",
"      Note:",
"     </b>",
"     The 5:1 ratio (SMX:TMP) remains constant in all dosage forms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: Sulfamethoxazole 80 mg and trimethoprim 16 mg per mL (5 mL, 10 mL, 30 mL) [contains benzyl alcohol, ethanol 12.2%, propylene glycol 400 mg/mL, sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: Sulfamethoxazole 200 mg and trimethoprim 40 mg per 5 mL (480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Tablet: Sulfamethoxazole 400 mg and trimethoprim 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bactrim&trade;: Sulfamethoxazole 400 mg and trimethoprim 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, double-strength: Sulfamethoxazole 800 mg and trimethoprim 160 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bactrim&trade; DS: Sulfamethoxazole 800 mg and trimethoprim 160 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Septra&reg; DS: Sulfamethoxazole 800 mg and trimethoprim 160 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F154861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Infuse diluted solution over 60-90 minutes; not for I.M. injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer without regard to meals. Administer with at least 8 ounces of water.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F154913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W,  D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, aldesleukin, allopurinol, amifostine, Aminosyn&reg; II, amphotericin B cholesteryl sulfate complex, anidulafungin, atracurium, aztreonam, bivalirudin, cefepime, cyclophosphamide, cyclosporine, dexmedetomidine, diltiazem, docetaxel, doxorubicin liposome, enalaprilat, esmolol, etoposide phosphate, fenoldopam, filgrastim, fludarabine, gallium nitrate, gemcitabine, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, labetalol, linezolid, lorazepam, magnesium sulfate, melphalan, meperidine, morphine, nicardipine, oxytocin, pancuronium, pemetrexed, piperacillin/tazobactam, remifentanil, sargramostim, tacrolimus, teniposide, thiotepa, vecuronium, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Caspofungin, fluconazole, midazolam, pantoprazole, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cisatracurium, foscarnet.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Dimenhydramine, heparin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F154860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral treatment of urinary tract infections due to",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      Klebsiella",
"     </i>",
"     and",
"     <i>",
"      Enterobacter",
"     </i>",
"     sp,",
"     <i>",
"      M. morganii",
"     </i>",
"     ,",
"     <i>",
"      P. mirabilis",
"     </i>",
"     and",
"     <i>",
"      P. vulgaris",
"     </i>",
"     ; acute otitis media in children; acute exacerbations of chronic bronchitis in adults due to susceptible strains of",
"     <i>",
"      H. influenzae",
"     </i>",
"     or",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     ; treatment and prophylaxis of",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia (PCP); traveler's diarrhea due to enterotoxigenic",
"     <i>",
"      E. coli",
"     </i>",
"     ; treatment of enteritis caused by",
"     <i>",
"      Shigella flexneri",
"     </i>",
"     or",
"     <i>",
"      Shigella sonnei",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V. treatment of severe or complicated infections when oral therapy is not feasible, for documented PCP, empiric treatment of PCP in immune compromised patients; treatment of documented or suspected shigellosis, typhoid fever, or other infections caused by susceptible bacteria",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F154904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cholera and",
"     <i>",
"      Salmonella",
"     </i>",
"     -type infections and nocardiosis; chronic prostatitis; as prophylaxis in neutropenic patients with",
"     <i>",
"      P. jirovecii",
"     </i>",
"     infections, in leukemia patients, and in patients following renal transplantation, to decrease incidence of PCP; treatment of",
"     <i>",
"      Cyclospora",
"     </i>",
"     infection, typhoid fever,",
"     <i>",
"      Nocardia asteroides",
"     </i>",
"     infection; prophylaxis against urinary tract infection; alternative treatment for  MRSA infections; oral phase treatment of prosthetic joint infection; chronic antimicrobial suppression of prosthetic joint infection",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F154917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Bactrim&trade; may be confused with bacitracin, Bactine&reg;, Bactroban&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Co-trimoxazole may be confused with clotrimazole",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Septra&reg; may be confused with Ceptaz, Sectral&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Septra&reg; DS may be confused with Semprex&reg;-D",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F154905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The most common adverse reactions include gastrointestinal upset (nausea, vomiting, anorexia) and dermatologic reactions (rash or urticaria). Rare, life-threatening reactions have been associated with co-trimoxazole, including severe dermatologic reactions, blood dyscrasias, and hepatotoxic reactions. Most other reactions listed are rare, however, frequency cannot be accurately estimated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Allergic myocarditis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Apathy, aseptic meningitis, ataxia, chills, depression, fatigue, fever, hallucinations, headache, insomnia, kernicterus (in neonates), nervousness, peripheral neuritis, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Photosensitivity, pruritus, rash, skin eruptions, urticaria; rare reactions include erythema multiforme, exfoliative dermatitis, Henoch-Sch&ouml;nlein purpura, Stevens-Johnson syndrome, and toxic epidermal necrolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia (generally at high dosages), hypoglycemia (rare), hyponatremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, glottitis, nausea, pancreatitis, pseudomembranous colitis, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, eosinophilia, hemolysis (with G6PD deficiency), hemolytic anemia, hypoprothrombinemia, leukopenia, megaloblastic anemia, methemoglobinemia, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatotoxicity (including hepatitis, cholestasis, and hepatic necrosis), hyperbilirubinemia, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia, rhabdomyolysis, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, crystalluria, diuresis (rare), interstitial nephritis, nephrotoxicity (in association with cyclosporine), renal failure, serum creatinine increased, toxic nephrosis (with anuria and oliguria)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, pulmonary infiltrates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, anaphylaxis, angioedema, periarteritis nodosa (rare), serum sickness, systemic lupus erythematosus (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F154864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any sulfa drug, trimethoprim, or any component of the formulation; megaloblastic anemia due to folate deficiency; infants &lt;2 months of age; marked hepatic damage or severe renal disease (if patient not monitored); pregnancy (at term); breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F154846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Fatalities associated with severe reactions including agranulocytosis, aplastic anemia, and other blood dyscrasias have occurred; discontinue use at first sign of rash or signs of serious adverse reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic reactions: Fatalities associated with severe reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have occurred; discontinue use at first sign of rash.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic necrosis: Fatalities associated with hepatic necrosis have occurred; discontinue use at first sign of rash or signs of serious adverse reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: May cause hyperkalemia (associated with high doses of trimethoprim).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: May cause hypoglycemia, particularly in malnourished, or patients with renal or hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Leucovorin: Avoid concomitant use when treating",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia (PCP) in HIV patients; may increase risk of treatment failure and death.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma/allergies: Use with caution in patients with allergies or asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended. Maintain adequate hydration to prevent crystalluria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; AIDS patients: Incidence of adverse effects appears to be increased in patients with AIDS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; greater risk for more severe adverse reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Use with caution in patients with G6PD deficiency; hemolysis may occur (dose-related).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patients with potential for folate deficiency: Use with caution in patients with potential folate deficiency (malnourished, chronic anticonvulsant therapy, or elderly).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Slow acetylators: May be more prone to adverse reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection vehicle: May contain benzyl alcohol which has been associated with \"gasping syndrome\" in neonates and sodium metabisulfite.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F154902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F154851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Trimethoprim may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amantadine: Trimethoprim may enhance the adverse/toxic effect of Amantadine. Specifically, the risk of myoclonus and/or delirium may be increased. Amantadine may increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Amantadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Trimethoprim may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Trimethoprim may decrease the metabolism of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: Sulfamethoxazole may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: Trimethoprim may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Sulfonamide Derivatives may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Sulfonamide Derivatives may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): May increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Dapsone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Topical): Trimethoprim may enhance the adverse/toxic effect of Dapsone (Topical). More specifically, trimethoprim may increase the risk for hemolysis",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Trimethoprim may decrease the excretion of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Trimethoprim may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Sulfonamide Derivatives may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Trimethoprim may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamiVUDine: Trimethoprim may decrease the excretion of LamiVUDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leucovorin Calcium-Levoleucovorin: May diminish the therapeutic effect of Trimethoprim. Management: Avoid concurrent use of leucovorin or levoleucovorin with trimethoprim (plus sulfamethoxazole) for",
"     <i>",
"      Pneumocystis jiroveci",
"     </i>",
"     pneumonia.  If trimethoprim is used for another indication, monitor closely for reduced efficacy.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Memantine: Trimethoprim may enhance the adverse/toxic effect of Memantine. Specifically, the risk of myoclonus and/or delirium may be increased. Memantine may increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Memantine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: Sulfamethoxazole may enhance the myelosuppressive effect of Mercaptopurine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: Trimethoprim may enhance the myelosuppressive effect of Mercaptopurine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Trimethoprim may increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: May enhance the adverse/toxic effect of Sulfonamide Derivatives. Specifically, the combination may result in the formation of an insoluble precipitate in the urine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Sulfonamide Derivatives may enhance the adverse/toxic effect of Methotrexate.  Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (eg, bone marrow suppression).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Trimethoprim may enhance the adverse/toxic effect of Methotrexate.  Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (e.g., bone marrow suppression).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Sulfonamide Derivatives may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Trimethoprim may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium P-Aminobenzoate: May diminish the therapeutic effect of Sulfonamide Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Trimethoprim may increase the serum concentration of PRALAtrexate. More specifically, trimethoprim may decrease excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum level and/or possible toxicity with concomitant use of trimethoprim. Monitor for decreased pralatrexate levels with discontinuation of trimethoprim.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Sulfamethoxazole may increase the serum concentration of PRALAtrexate. More specifically, sulfamethoxazole may decrease excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum level and/or possible toxicity with concomitant use of sulfamethoxazole. Monitor for decreased pralatrexate levels with discontinuation of sulfamethoxazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procainamide: Trimethoprim may increase serum concentrations of the active metabolite(s) of Procainamide. Trimethoprim may increase the serum concentration of Procainamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procaine: May diminish the therapeutic effect of Sulfonamide Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Trimethoprim may decrease the metabolism of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: Trimethoprim may enhance the hyperkalemic effect of Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Sulfonamide Derivatives may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varenicline: Trimethoprim may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concomitant use of trimethoprim, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Sulfonamide Derivatives may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F154880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid dong quai; St John's wort (may diminish effects and also cause photosensitization).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F154854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F154867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies; therefore, the manufacturer classifies TMP-SMX as pregnancy category C. TMP-SMX crosses the placenta and distributes to amniotic fluid. Due to trimethoprim&rsquo;s potential effect on folic acid metabolism, TMP-SMX should only be used during pregnancy if the benefit justifies the potential risk. The use of dihydrofolate reductase inhibitors, including trimethoprim, during pregnancy may increase the risk of congenital anomalies including cardiovascular defects, oral clefts, urinary tract anomalies, and neural tube defects. Folic acid supplementation may decrease this risk. A few case reports have described additional congenital anomalies after TMP-SMX exposure, but none of these have proven causality. Most studies and case reports have failed to show an increased risk for congenital malformations after use of TMP-SMX. Per the manufacturer, TMP-SMX is contraindicated in late pregnancy because sulfonamides pass the placenta and may cause kernicterus in the newborn, but this has not been observed specifically with SMX. Neonatal healthcare providers should be informed if maternal sulfonamide therapy is used near the time of delivery. TMP-SMX may be used in pregnancy for prophylaxis or treatment of",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia (PCP), the prophylaxis of",
"     <i>",
"      Toxoplasmic gondii",
"     </i>",
"     encephalitis (TE), and may prevent fetal loss in patients with Q fever (",
"     <i>",
"      Coxiella burnetii",
"     </i>",
"     ). The pharmacokinetics of TMP-SMX are similar to nonpregnant values in early pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F154896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F154868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of TMP and SMX are transferred to breast milk. Per the manufacturer, TMP-SMX is contraindicated in nursing mothers since sulfonamides cross into the milk and may cause kernicterus in the newborn. Because TMP-SMX has therapeutic indications for infants &ge;2 months of age, kernicterus after exposure via breast-feeding would not be expected in healthy infants of this age group; however, sulfonamides should not be used while nursing an infant with G6PD deficiency or hyperbilirubinemia. Nondose related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F154869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with 8 oz of water. May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F154866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sulfamethoxazole-Trimethoprim Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400-80 mg/5 mL (10 mL): $7.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Sulfamethoxazole-Trimethoprim Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200-40 mg/5 mL (473 mL): $58.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Bactrim DS Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     800-160 mg (100): $311.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Bactrim Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400-80 mg (100): $172.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sulfamethoxazole-Trimethoprim Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400-80 mg (100): $66.45",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6059143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Perform culture and sensitivity testing prior to initiating therapy; CBC, serum potassium, creatinine, BUN",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F154870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Abacin (IT);",
"     </li>",
"     <li>",
"      Acuco (ZA);",
"     </li>",
"     <li>",
"      Alcorim-F (IN);",
"     </li>",
"     <li>",
"      Anitrim (MX);",
"     </li>",
"     <li>",
"      Bacin (MY, SG, TH);",
"     </li>",
"     <li>",
"      Bactelan (MX);",
"     </li>",
"     <li>",
"      Bacteric (MX);",
"     </li>",
"     <li>",
"      Bacterol (CN);",
"     </li>",
"     <li>",
"      Bacterol Forte (CN);",
"     </li>",
"     <li>",
"      Bacticel (AR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Bactiver (MX);",
"     </li>",
"     <li>",
"      Bactramin (JP);",
"     </li>",
"     <li>",
"      Bactrim (AE, AR, AT, AU, BE, BH, CH, CY, CZ, DE, DK, EC, EE, EG, ES, FR, ID, IN, IQ, IR, IT, JO, KW, LB, LY, MT, MX, NO, OM, PK, PT, QA, SA, SE, SK, SY, TH, TR, YE);",
"     </li>",
"     <li>",
"      Bactrim DS (AU);",
"     </li>",
"     <li>",
"      Bactrim F (CO);",
"     </li>",
"     <li>",
"      Bactrim Forte (AT, FI, FR, PT, SE);",
"     </li>",
"     <li>",
"      Bactrimel (GR, VE);",
"     </li>",
"     <li>",
"      Bactropin (MX);",
"     </li>",
"     <li>",
"      Biseptol (BG);",
"     </li>",
"     <li>",
"      Brogamax (MX);",
"     </li>",
"     <li>",
"      Colizole (IN);",
"     </li>",
"     <li>",
"      Colizole DS (IN);",
"     </li>",
"     <li>",
"      Cotrim (BF, BJ, CI, ET, GH, GM, GN, KE, KP, LR, MA, ML, MR, MU, MW, MY, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Cotrim DS (MY);",
"     </li>",
"     <li>",
"      Cotrimel (HK);",
"     </li>",
"     <li>",
"      Cotrix (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Cotrizol (TW);",
"     </li>",
"     <li>",
"      Dibaprim (MX);",
"     </li>",
"     <li>",
"      Diseptyl (IL);",
"     </li>",
"     <li>",
"      Duratrimet (DE);",
"     </li>",
"     <li>",
"      Ectaprim (MX);",
"     </li>",
"     <li>",
"      Epitrim (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Escoprim (CH);",
"     </li>",
"     <li>",
"      Espectrin (BR);",
"     </li>",
"     <li>",
"      Eusaprim (AT, BE, FI, IT, NO, SE);",
"     </li>",
"     <li>",
"      Fectrim (GB);",
"     </li>",
"     <li>",
"      Gantaprim (IT);",
"     </li>",
"     <li>",
"      Gantrim (IT);",
"     </li>",
"     <li>",
"      Ikaprim (ID);",
"     </li>",
"     <li>",
"      Infectrim (PE);",
"     </li>",
"     <li>",
"      Introcin (CN);",
"     </li>",
"     <li>",
"      Isotrim (IT);",
"     </li>",
"     <li>",
"      Kepinol (DE);",
"     </li>",
"     <li>",
"      Lagatrim (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Lagatrim Forte (BB, BF, BJ, BM, BS, BZ, CI, ET, GH, GM, GN, GY, JM, KE, LR, MA, ML, MR, MU, MW, NE, NG, NL, PR, SC, SD, SL, SN, SR, TN, TT, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Mano-Trim (TH);",
"     </li>",
"     <li>",
"      Mano-Trim Forte (TH);",
"     </li>",
"     <li>",
"      Medixin (IT);",
"     </li>",
"     <li>",
"      Metoxiprim (MX);",
"     </li>",
"     <li>",
"      Metrim (TH);",
"     </li>",
"     <li>",
"      Microtrim (DE);",
"     </li>",
"     <li>",
"      Morbifurb (CL);",
"     </li>",
"     <li>",
"      Nopil (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Octex (MX);",
"     </li>",
"     <li>",
"      Omsat (BF, BJ, CI, DE, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Oriprim (RU);",
"     </li>",
"     <li>",
"      Oriprim DS (KE, TZ, UG, ZW);",
"     </li>",
"     <li>",
"      Oxaprim (IT);",
"     </li>",
"     <li>",
"      Primzole (SG);",
"     </li>",
"     <li>",
"      Purbal (ZA);",
"     </li>",
"     <li>",
"      Resprim (AU);",
"     </li>",
"     <li>",
"      Resprim Forte (AU);",
"     </li>",
"     <li>",
"      Sanprima (ID);",
"     </li>",
"     <li>",
"      Sanprima Forte (ID);",
"     </li>",
"     <li>",
"      Septran (IN, PK, PY);",
"     </li>",
"     <li>",
"      Septran Forte (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Septrin (AE, AU, BF, BH, BJ, CI, CY, EG, ES, ET, GB, GH, GM, GN, ID, IE, IQ, IR, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, NE, NG, OM, PE, PH, QA, SA, SC, SD, SG, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Septrin DS (HK);",
"     </li>",
"     <li>",
"      Septrin Forte (AU);",
"     </li>",
"     <li>",
"      Servitrim (MX);",
"     </li>",
"     <li>",
"      Sigaprim (DE);",
"     </li>",
"     <li>",
"      Soltrim (MX);",
"     </li>",
"     <li>",
"      Suftrex (EC);",
"     </li>",
"     <li>",
"      Sulfacet (DE);",
"     </li>",
"     <li>",
"      Sulfoid Trimetho (MX);",
"     </li>",
"     <li>",
"      Sulfotrimin (DE);",
"     </li>",
"     <li>",
"      Suntrim (TH);",
"     </li>",
"     <li>",
"      Suntrim Forte (TH);",
"     </li>",
"     <li>",
"      Suprim (PE);",
"     </li>",
"     <li>",
"      Suprin (IT);",
"     </li>",
"     <li>",
"      Timexole (MX);",
"     </li>",
"     <li>",
"      TMS (DE);",
"     </li>",
"     <li>",
"      Trim (IT, ZA);",
"     </li>",
"     <li>",
"      Trimaxazole (SG);",
"     </li>",
"     <li>",
"      Trimetoger (MX);",
"     </li>",
"     <li>",
"      Trimexazol (MX);",
"     </li>",
"     <li>",
"      Trimexazole (TH);",
"     </li>",
"     <li>",
"      Trimezol (BG);",
"     </li>",
"     <li>",
"      Trimoprim (HK);",
"     </li>",
"     <li>",
"      Trimoxis (PH);",
"     </li>",
"     <li>",
"      Trisolvat (CO);",
"     </li>",
"     <li>",
"      Trisul (NZ);",
"     </li>",
"     <li>",
"      Trizole (PH);",
"     </li>",
"     <li>",
"      Xepaprim (ID);",
"     </li>",
"     <li>",
"      Xepaprim Forte (ID);",
"     </li>",
"     <li>",
"      Zoltrim (EC);",
"     </li>",
"     <li>",
"      Zultrop (ID);",
"     </li>",
"     <li>",
"      Zultrop Forte (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F154845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sulfamethoxazole interferes with bacterial folic acid synthesis and growth via inhibition of dihydrofolic acid formation from para-aminobenzoic acid; trimethoprim inhibits dihydrofolic acid reduction to tetrahydrofolate resulting in sequential inhibition of enzymes of the folic acid pathway",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F154863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Almost completely, 90% to 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: SMX: 68%, TMP: 45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: SMX: N-acetylated and glucuronidated; TMP: Metabolized to oxide and hydroxylated metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: SMX: 9 hours, TMP: 6-17 hours; both are prolonged in renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Within 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Both are excreted in urine as metabolites and unchanged drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Effects of aging on the pharmacokinetics of both agents has been variable; increase in half-life and decreases in clearance have been associated with reduced creatinine clearance",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;American Academy of Pediatrics and American Academy of Family Physicians. Diagnosis and Management of Acute Otitis Media,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 113(5):1451-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/15121972/pubmed\" id=\"15121972\" target=\"_blank\">",
"        15121972",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007: 154.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bissuel F, Cotte L, Crapanne JB, et al, &ldquo;Trimethoprim-Sulphamethoxazole Rechallenge in 20 Previously Allergic HIV-Infected Patients After Homeopathic,&rdquo;",
"      <i>",
"       AIDS",
"      </i>",
"      , 1995, 9(4):407-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/7794554/pubmed\" id=\"7794554\" target=\"_blank\">",
"        7794554",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(4):1-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/19357635/pubmed\" id=\"19357635\" target=\"_blank\">",
"        19357635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Sexually Transmitted Diseases Treatment Guidelines, 2006,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 55(RR-11):1-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/16888612/pubmed\" id=\"16888612\" target=\"_blank\">",
"        16888612",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Choo V, &ldquo;UK Revises Indications for Co-Trimoxazole,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1995, 346(8968):175.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cockerill FR and Edson RS, &ldquo;Trimethoprim-Sulfamethoxazole,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1991, 66(12):1260-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/1749295/pubmed\" id=\"1749295\" target=\"_blank\">",
"        1749295",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cook DE and Ponte CD, &ldquo;Suspected Trimethoprim/Sulfamethoxazole-Induced Hypoprothrombinemia,&rdquo;",
"      <i>",
"       J Fam Pract",
"      </i>",
"      , 1994, 39(6):589-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/7798864/pubmed\" id=\"7798864\" target=\"_blank\">",
"        7798864",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cordero-Ampuero J, Esteban J, Garcia-Cimbrelo E, et al.  &ldquo;Low Relapse With Oral Antibiotics and Two-Stage Exchange for Late Arthroplasty Infections in 40 Patients After 2-9 Years,&rdquo;",
"      <i>",
"       Acta Orthopaedica",
"      </i>",
"      ,  2007, 78(4):511-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/17966006/pubmed\" id=\"17966006\" target=\"_blank\">",
"        17966006",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dawkins B, Albury D, and Olsen TE, &ldquo;Trimethoprim/Sulfamethoxazole-Induced Thrombocytopenia - A Case Report Supported by the Laboratory Diagnosis,&rdquo;",
"      <i>",
"       Aust N Z J Med",
"      </i>",
"      , 1995, 25:83.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Domingo P, Ferrer S, Cruz J, et al, &ldquo;Trimethoprim-Sulfamethoxazole-Induced Renal Tubular Acidosis in a Patient With AIDS,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1995, 20(5):143, 45-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/7727640/pubmed\" id=\"7727640\" target=\"_blank\">",
"        7727640",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fischl MA, Dickinson GM, and La Voie L, &ldquo;Safety and Efficacy of Sulfamethoxazole and Trimethoprim Chemoprophylaxis for",
"      <i>",
"       Pneumocystis carinii",
"      </i>",
"      Pneumonia in AIDS,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1988, 259(8):1185-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/3257532/pubmed\" id=\"3257532\" target=\"_blank\">",
"        3257532",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hennessy S, Strom BL, Berlin JA, et al, &ldquo;Predicting Cutaneous Hypersensitivity Reactions to Co-Trimoxazole in HIV-Infected Individuals Receiving Primary",
"      <i>",
"       Pneumocystis carinii",
"      </i>",
"      Pneumonia Prophylaxis,&rdquo;",
"      <i>",
"       J Gen Intern Med",
"      </i>",
"      , 1995, 10(7):380-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/7472686/pubmed\" id=\"7472686\" target=\"_blank\">",
"        7472686",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hughes W, Leoung G, Kramer F, et al, &ldquo;Comparison of Atovaquone (566C80) With Trimethoprim-Sulfamethoxazole to Treat",
"      <i>",
"       Pneumocystis carinii",
"      </i>",
"      Pneumonia in Patients With AIDS,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 328(21):1521-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/8479489/pubmed\" id=\"8479489\" target=\"_blank\">",
"        8479489",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hughes WT, &ldquo;",
"      <i>",
"       Pneumocystis carinii",
"      </i>",
"      Pneumonia: New Approaches to Diagnosis, Treatment, and Prevention,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1991, 10(5):391-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/2067889/pubmed\" id=\"2067889\" target=\"_blank\">",
"        2067889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jick H and Derby LE, &ldquo;A Large Population-Based Follow-Up Study of Trimethoprim-Sulfamethoxazole, Trimethoprim, and Cephalexin for Uncommon Serious Drug Toxicity,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1995, 15(4):428-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/7479194/pubmed\" id=\"7479194\" target=\"_blank\">",
"        7479194",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jick H and Derby LE, &ldquo;Is Co-Trimoxazole Safe?&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1995, 345(8957):1118-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/7715367/pubmed\" id=\"7715367\" target=\"_blank\">",
"        7715367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lerner PI, &ldquo;Nocardiosis,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1996, 22(6):891-903.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/8783685/pubmed\" id=\"8783685\" target=\"_blank\">",
"        8783685",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Li PK, Szeto CC, Piraino B, et al, \"Peritoneal Dialysis-Related Infections Recommendations: 2010 Update,\"",
"      <i>",
"       Perit Dial Int",
"      </i>",
"      , 2010, 30(4):393-423",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/20628102/pubmed\" id=\"20628102\" target=\"_blank\">",
"        20628102",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipsky BA, Berendt AR, Cornia PB, et al, \"2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012, 54(12):e132-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/22619242/pubmed\" id=\"22619242\" target=\"_blank\">",
"        22619242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu C, Bayer A, Cosgrove SE, et al, &ldquo;Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant",
"      <i>",
"       Staphylococcus Aureus",
"      </i>",
"      Infections in Adults and Children: Executive Summary,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 52(3):285-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/21217178/pubmed\" id=\"21217178\" target=\"_blank\">",
"        21217178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Looney WJ, Narita M, and Muhlemann K, \"",
"      <i>",
"       Stenotrophomonas maltophilia",
"      </i>",
"      : An Emerging Opportunist Human Pathogen,\"",
"      <i>",
"       Lancet Infect Dis",
"      </i>",
"      , 2009, 9(5):312-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/19393961/pubmed\" id=\"19393961\" target=\"_blank\">",
"        19393961",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lundstrom TS and Sobel JD, &ldquo;Vancomycin, Trimethoprim-Sulfamethoxazole, and Rifampin,&rdquo;",
"      <i>",
"       Infect Dis Clin North Am",
"      </i>",
"      , 1995, 9(3):747-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/7490442/pubmed\" id=\"7490442\" target=\"_blank\">",
"        7490442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Masur H, &ldquo;Prevention and Treatment of",
"      <i>",
"       Pneumocystis",
"      </i>",
"      Pneumonia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1992, 327(26):1853-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/1448123/pubmed\" id=\"1448123\" target=\"_blank\">",
"        1448123",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Naber K, Vergin H, and Weigand W, &ldquo;Pharmacokinetics of Co-trimoxazole and Co-tetroxazine in Geriatric Patients,&rdquo;",
"      <i>",
"       Infection",
"      </i>",
"      , 1981, 9(5):239-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/6975241/pubmed\" id=\"6975241\" target=\"_blank\">",
"        6975241",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nahata MC, &ldquo;Dosing Regimens of Trimethoprim/Sulfamethoxazole (TPM/SMX) in Patients With Renal Dysfunction.,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(12):1300.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/8672842/pubmed\" id=\"8672842\" target=\"_blank\">",
"        8672842",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Noto H, Kaneko Y, Takano T, et al, &ldquo;Severe Hyponatremia and Hyperkalemia Induced by Trimethoprim-Sulfamethoxazole in Patients With",
"      <i>",
"       Pneumocystis carinii",
"      </i>",
"      Pneumonia,&rdquo;",
"      <i>",
"       Intern Med",
"      </i>",
"      , 1995, 34(2):96-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/7727887/pubmed\" id=\"7727887\" target=\"_blank\">",
"        7727887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2013, 56(1):e1-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/23223583/pubmed\" id=\"23223583\" target=\"_blank\">",
"        23223583",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pape JW, Verdier RI, Boncy M, et al, &ldquo;Cyclospora Infection in Adults Infected with HIV. Clinical Manifestations, treatment, and Prophylaxis,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1994, 121(9):654-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/7944073/pubmed\" id=\"7944073\" target=\"_blank\">",
"        7944073",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Practice Parameter: The Diagnosis, Treatment, and Evaluation of the Initial Urinary Tract Infection in Febrile Infants and Young Children. American Academy of Pediatrics, Committee on Quality Improvement, Subcommittee on Urinary Tract Infection,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1999, 103(4 Pt 1):843-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/10103321/pubmed\" id=\"10103321\" target=\"_blank\">",
"        10103321",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sattler FR, Cowan R, Nielsen DM, et al, &ldquo;Trimethoprim-Sulfamethoxazole Compared With Pentamidine for Treatment of",
"      <i>",
"       Pneumocystis carinii",
"      </i>",
"      Pneumonia in the Acquired Immunodeficiency Syndrome,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1988, 109(4):280-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/3260759/pubmed\" id=\"3260759\" target=\"_blank\">",
"        3260759",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh N, Gayowski T, Yu VL, et al, &ldquo;Trimethoprim-Sulfamethoxazole for the Prevention of Spontaneous Bacterial Peritonitis in Cirrhosis: A Randomized Trial,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1995, 122(8):595-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/7887554/pubmed\" id=\"7887554\" target=\"_blank\">",
"        7887554",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stevens DL, Bisno AL, Chambers HF, et al, &ldquo;Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005; 41(10):1373&ndash;406.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/16231249/pubmed\" id=\"16231249\" target=\"_blank\">",
"        16231249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Torre D, Casari S, Speranza F, et al, &ldquo;Randomized Trial of Trimethoprim-Sulfamethoxazole Versus Pyrimethamine-Sulfadiazine for Therapy of Toxoplasmic Encephalitis in Patients With AIDS. Italian Collaborative Study Group,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1998, 42(6):1346-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/9624473/pubmed\" id=\"9624473\" target=\"_blank\">",
"        9624473",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, \"Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2004, 39(9):1267-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/15494903/pubmed\" id=\"15494903\" target=\"_blank\">",
"        15494903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Varoquaux O, Lajoie D, Gobert C, et al, &ldquo;Pharmacokinetics of the Trimethoprim-Sulfamethoxazole Combination in the Elderly,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1985, 20(6):575-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/3879182/pubmed\" id=\"3879182\" target=\"_blank\">",
"        3879182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vartivarian S, Anaissie E, Bodey G, et al, \"A Changing Pattern of Susceptibility of",
"      <i>",
"       Xanthomonas maltophilia",
"      </i>",
"      to Antimicrobial Agents: Implications for Therapy,\"",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1994, 38(3):624-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/8203865/pubmed\" id=\"8203865\" target=\"_blank\">",
"        8203865",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Verdier RI, Fritzgerald DW, Johnson WD, et al, &ldquo; Trimethoprim-Sulfamethoxazole Compared With Ciprofloxacin for Treatment and Prophylaxis of",
"      <i>",
"       Isospora belli",
"      </i>",
"      and",
"      <i>",
"       Cyclospora cayetanensis",
"      </i>",
"      Infection in HIV-Infected Patients,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2000, 132(11):885-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/10836915/pubmed\" id=\"10836915\" target=\"_blank\">",
"        10836915",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Warady BA, Schaefer F, Holloway M, et al, \"Consensus Guidelines for the Treatment of Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis,\"",
"      <i>",
"       Perit Dial Int",
"      </i>",
"      , 2000, 20(6):610-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/11216549/pubmed\" id=\"11216549\" target=\"_blank\">",
"        11216549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wood GC, Underwood EL, Croce MA, et al, \"Treatment of Recurrent",
"      <i>",
"       Stenotrophomonas maltophilia",
"      </i>",
"      Ventilator-Associated Pneumonia With Doxycycline and Aerosolized Colistin,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2010, 44(10):1665-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/58/5034/abstract-text/20736426/pubmed\" id=\"20736426\" target=\"_blank\">",
"        20736426",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9785 Version 51.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-AA4CF5E739-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_58_5034=[""].join("\n");
var outline_f4_58_5034=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154885\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154886\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154907\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154889\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154900\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154890\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154891\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154857\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154842\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154861\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154913\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154860\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154904\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154917\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154905\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154864\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154846\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154902\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154851\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154880\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154854\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154867\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154896\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154868\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154869\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154866\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6059143\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154870\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154845\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154863\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9785\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9785|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/2/23589?source=related_link\">",
"      Trimethoprim-sulfamethoxazole (co-trimoxazole): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=related_link\">",
"      Trimethoprim-sulfamethoxazole (co-trimoxazole): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_58_5035="Phadia IgE immunoassay classes";
var content_f4_58_5035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F71100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F71100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Phadia IgE immunoassay classes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       IgE class (by Phadia)",
"      </td>",
"      <td class=\"subtitle1\">",
"       IgE concentration (kIU/L)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       &lt;0.35",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       0.35 - 0.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       0.7 - 3.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       3.5 - 17.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       17.5 - 50",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       50 - 100",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       &gt;100",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_58_5035=[""].join("\n");
var outline_f4_58_5035=null;
var title_f4_58_5036="Transcutaneous pacemaker indications";
var content_f4_58_5036=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for placement of transcutaneous patches* and active (demand) transcutaneous pacing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Sinus bradycardia (rate less than 50 bpm) with",
"symptoms of hypotension (systolic blood pressure less than 80 mm Hg)",
"unresponsive to drug therapy.&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Mobitz type II second-degree AV block.&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Third-degree heart block.&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Bilateral BBB (alternating BBB, or RBBB and",
"alternating left anterior fascicular block [LAFB], left posterior",
"fascicular block [LPFB]) irrespective of time of onset).*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Newly aquired or age indeterminate LBBB, LBBB and",
"LAFB, RBBB and LPFB.*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. RBBB or LBBB and first-degree AV block.*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Stable bradycardia (systolic blood pressure greater",
"than 90 mm Hg, no hemodynamic compromise, or compromise responsive to",
"initial drug therapy).*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Newly acquired or age-indeterminate first-degree AV",
"block.*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Uncomplicated acute MI without evidence of",
"conduction system disease.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Transcutaneous patches applied; system may be attached and activated within a brief time if needed. Transcutaneous pacing may be very helpful as an urgent expedient. Because it is associated with significant pain, high-risk patients likely to require pacing should receive a temporary transvenous pacemaker.",
"     <br>",
"      &bull;&nbsp;Apply patches and attach system; system is in either active or standby mode to allow immediate use on demand as required. In facilities in which transvenous pacing or expertise are available, consideration should be given to placing a transvenous system.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     From Ryan, TJ, Anderson, JL, Antman, EM, et al, JACC 1996; 28:1367.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_58_5036=[""].join("\n");
var outline_f4_58_5036=null;
var title_f4_58_5037="Mastectomy chest wall XRT";
var content_f4_58_5037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F55536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F55536&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Older randomized trials of mastectomy with or without radiotherapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Trial",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Years of accrual",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Number of patients randomized",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Surgery",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Radiotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Site",
"       </td>",
"       <td class=\"subtitle2\">",
"        Energy",
"       </td>",
"       <td class=\"subtitle2\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oslo I*",
"       </td>",
"       <td>",
"        1964-67",
"       </td>",
"       <td>",
"        546",
"       </td>",
"       <td>",
"        RM",
"       </td>",
"       <td>",
"        CW, RN",
"       </td>",
"       <td>",
"        200 kV",
"       </td>",
"       <td>",
"        25-41 Gy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oslo II*",
"       </td>",
"       <td>",
"        1968-72",
"       </td>",
"       <td>",
"        542",
"       </td>",
"       <td>",
"        RM",
"       </td>",
"       <td>",
"        RN",
"       </td>",
"       <td>",
"        MV",
"       </td>",
"       <td>",
"        50 Gy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NSABP BO2&bull;",
"       </td>",
"       <td>",
"        1961-68",
"       </td>",
"       <td>",
"        787",
"       </td>",
"       <td>",
"        RM",
"       </td>",
"       <td>",
"        RN",
"       </td>",
"       <td>",
"        kV/MV",
"       </td>",
"       <td>",
"        35-45 Gy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stockholm&Delta;",
"       </td>",
"       <td>",
"        1971-76",
"       </td>",
"       <td>",
"        960",
"       </td>",
"       <td>",
"        MRM",
"       </td>",
"       <td>",
"        B/CW, RN",
"       </td>",
"       <td>",
"        MV",
"       </td>",
"       <td>",
"        45 Gy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Manchester&loz;",
"       </td>",
"       <td>",
"        1970-75",
"       </td>",
"       <td>",
"        714",
"       </td>",
"       <td>",
"        TM",
"       </td>",
"       <td>",
"        CW, RN",
"       </td>",
"       <td>",
"        kV/MV",
"       </td>",
"       <td>",
"        37 Gy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cancer Research Campaign&sect;",
"       </td>",
"       <td>",
"        1970-75",
"       </td>",
"       <td>",
"        2800",
"       </td>",
"       <td>",
"        TM",
"       </td>",
"       <td>",
"        CW, RN",
"       </td>",
"       <td>",
"        kV/MV",
"       </td>",
"       <td>",
"        28-46 Gy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NSABP B04&yen;",
"       </td>",
"       <td>",
"        1971-74",
"       </td>",
"       <td>",
"        717",
"       </td>",
"       <td>",
"        TM",
"       </td>",
"       <td>",
"        CW, RN",
"       </td>",
"       <td>",
"        MV",
"       </td>",
"       <td>",
"        50 Gy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Southampton&Dagger;",
"       </td>",
"       <td>",
"        1973-?",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        TM",
"       </td>",
"       <td>",
"        CW, RN",
"       </td>",
"       <td>",
"        MV",
"       </td>",
"       <td>",
"        46 Gy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Edinburgh&brvbar;",
"       </td>",
"       <td>",
"        1974-79",
"       </td>",
"       <td>",
"        226",
"       </td>",
"       <td>",
"        TM",
"       </td>",
"       <td>",
"        CW, RN",
"       </td>",
"       <td>",
"        MV",
"       </td>",
"       <td>",
"        42.5-45 Gy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CW: chest wall; B/CW: breast/chest wall; RN: regional nodes; RM: radical mastectomy; MRM, modified radical mastectomy; TM: total mastectomy.",
"    </div>",
"    <div class=\"reference\">",
"     * Int J Rad Oncol Biol Phys 1986; 12:727.",
"     <br>",
"      &bull; Ann Surg 1970; 172:711.",
"      <br>",
"       &Delta; Radiother Oncol 1993; 26:104.",
"       <br>",
"        &loz; Br J Surg 1982; 69;693.",
"        <br>",
"         &sect; World J Surg 1994; 18:117.",
"         <br>",
"          &yen; N Engl J Med 1995; 312:674.",
"          <br>",
"           &Dagger; Lancet 1978; 2:7-9.",
"           <br>",
"            &brvbar; Ann Surg 1982; 196;371.",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_58_5037=[""].join("\n");
var outline_f4_58_5037=null;
var title_f4_58_5038="Trends in cigarette smoking";
var content_f4_58_5038=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65613&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Trends in cigarette smoking among persons &ge;18 years old, by gender - United States, 1955-2006",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 304px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Before 1992, current smokers were defined as persons who reported having smoked &ge;100 cigarettes during their lifetime and who reported smoking every day or some days.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Cigarette smoking among adults-United States, 2006. MMWR Morb Mortal Wkly Rep, November 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_58_5038=[""].join("\n");
var outline_f4_58_5038=null;
var title_f4_58_5039="Typ carcinoid bronchoscopy";
var content_f4_58_5039=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Typical carcinoid at bronchoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles F Thomas, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_58_5039=[""].join("\n");
var outline_f4_58_5039=null;
